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Fibrodysplasia ossificans progressiva (FOP) is a rare disease in which heterotopic ossification 
(HO) forms in muscles, tendons and ligaments. In the past decade, knowledge about its 
pathophysiology has greatly improved and clinical trials to slow down or even stop disease 
progression are now emerging. The natural course of the disease, however, is not known. 
Moreover, a marker for the disease’s biological activity is not yet available. This lack of an 
imaging biomarker of FOP forms the basis of this thesis in which promising imaging 
techniques were investigated for studying the development of HO during the natural course 
of the disease.
Clinical aspects 
FOP is an autosomal dominant disease with a prevalence of 1.5 to 2 per million persons(1-4). 
The first phenotypic sign of FOP is the congenital monophalangic hallux valgus(3,5-7). In the 
majority of patients, this deformity is not recognised as a sign of FOP(8). Often, a diagnostic 
trajectory is not started before the first signs of disease activity become apparent. Although 
the age at which this disease activity, better known as a ‘flare-up’, is noticed varies greatly, 
the mean age is thought to be around 6 years(6,9). A flare-up is an inflammatory process of 
which the pathophysiology is not completely understood(9,10). Typically, flare-ups are 
presented with symptoms of redness, swelling and pain(10). Flare-ups can arise spontaneously 
or be triggered by trauma and infection(9). Although a proportion of flare-ups resolve without 
sequelae, the majority is followed by the formation of HO(9). This HO forms in muscles, 
tendons and ligaments, limiting mobility especially when located in or around a joint(7). 
Initially, flare-ups affect the thoracic region, neck and back but with aging, flare-ups, and 
thus HO formation, occur more distally, affecting shoulders, hips, elbows and knees(9). Due 
to its progressive character, patients often are wheelchair bound at the age of 30(11) and, 
life-expectancy is limited(12). The progressive ossification around the thorax restricts normal 
lung expansion. This results in a restrictive pulmonary function, which is thought to result 
in pulmonary hypertension and right decompensatio cordis (12-14). It is generally accepted 
that cardiorespiratory complications are the main cause of premature death in FOP patients. 
At present, there is no effective treatment to prevent flare-ups or to avoid HO development. 
Currently, glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) are used in 
an attempt to prevent disease progression(10,15). Its effectiveness, however, has never been 
investigated. 
Pathophysiology
From 2006 on, the understanding of the disease has expanded extensively based on the 
discovery of the underlying genetic mutation. Ninety-five percent of the FOP patients share 
the same mutation, the ‘classic mutation’. The remaining five percent has one of the twelve 
‘variant’ mutations(16). All FOP mutations are located in the Activin A receptor type 1 (ACVR1) 




Activin receptor-like kinase-2 (ALK2)(17). This receptor is a serine/threonine kinase receptor 
consisting of functional domains. It has an n-terminal domain for ligand binding, a 
transmembrane domain and a cytoplasmic C-terminal kinase domain. The latter consist of 
a glycine-serine (GS) domain and a protein kinase domain(18). The FOP mutation is located 
in the cytoplasmic C-terminal kinase domain, with the majority of mutations (including the 
classic mutation) in the GS domain(17). The classic mutation is a missense mutation that 
encodes for Histidine instead of Arginine (R206H)(17). Patients with a variant mutation might 
be either phenotypically similar to patients with the classical mutation, or have additional 
developmental abnormalities, e.g. alopecia, nail dysplasia or learning disorders(16). It is 
hypothesized that the severity of HO formation and progression depends on the location 
of the mutation. However, environmental factors are also known to play a crucial role(19).
Normally, a BMP type I/ALK2 receptor dimer forms a complex with a BMP type II dimer upon 
binding a ligand like BMP. Once bound, the type II receptors phosphorylate the GS domain 
of the BMP type 1 receptors. This phosphorylation activates the type 1 receptors, resulting 
in induction of the BMP pathway. This BMP pathway includes SMAD 1/5/8 and p38 mitogen-
activated protein kinase (MAPK) signalling(18,20), which, both directly and indirectly, promote 
transcription of genes involved in osteogenesis. When no BMP is bound to the receptor 
complex, the FK506 binding protein 12 (FKBP12) binds to the GS domain, inactivating the 
receptor. In addition, through SMAD7-Smurf1, FKBP12 regulates the number of ALK1 
receptors on the cell membrane. FKBP12 dissociates from the GS domain and forms a 
complex with FK506 when a ligand is bound to the receptor complex and the GS domain is 
phosphorylated (21,22). Apart from BMP, Activin A can act as a ligand for the receptor complex 
as well. Activin A is secreted by immune cells and is released at sites of tissue damage. When 
bound to the ALK1/ALK2 receptor complex, it does not activate the SMAD 1/5/8 pathway, 
but instead inhibits signalling by the receptor. Activin A thus competes with BMP for binding 
to the receptors(18). In the presence of the FOP mutation, the GS domain or its direct 
environment is altered due to the missense mutation. Due to the altered GS domain, FKBP12 
cannot bind anymore to inhibit signaling in the absence of a ligand. This causes a constitutive 
activity of BMP signaling. (23). In addition, once BMP binds, there is a hypersensitive reaction 
leading to stronger BMP signalling (Figure 1). Finally, in the presence of an ALK2-mutation, 
Activin A loses its inhibitory role and instead activates SMAD1/5/8(24). Through all these 
processes, osteogenesis is enhanced, resulting in the formation of HO. 
Heterotopic Ossification
The main characteristic of FOP disease activity is a flare-up and the successive formation of 
HO(7,9,11). Flare-ups may develop spontaneously, can be provoked by a viral infection (i.e. 
influenza) or can be triggered by a local trauma that damages muscle, tendon or ligamentous 
structures (9). Traumas that cause sufficient tissue damage are, for instance, a fall or a medical 
intervention (e.g. intramuscular immunization or surgical intervention)(8,9,25). Effects of local 
tissue damage on disease activity locally or elsewhere in the body are largely unknown due 
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to the lack of a marker of disease activity. The formation of HO after a flare-up can be 
evaluated with conventional radiographs, X-rays, or computed tomography (CT) scans(26-28). 
These techniques, however, only image outcome, and not local and systemically biological 
activity associated with the disease. Bone biopsies to evaluate local biological activity of 
bone is contraindicated in FOP, as it may trigger a flare-up. As biopsies are contraindicated, 
the developmental stages of HO have been unknown for a long time. However, by collecting 
biopsies obtained of a flare-up in yet undiagnosed FOP patients, more is known about the 
developmental stages. In the early phase of a flare-up, macrophages, mast cells and 
lymphocytes infiltrate the lesion and induce apoptosis of the cells. This phase is followed 
by fibroblast proliferation and extensive angiogenesis and neovascularisation(29,30). In the 
final phases, the lesion matures and the fibroproliferative tissue develops into cartilage 
before it further develops through osteogenesis to the form HO. Formed HO, is thought to 
resemble normal skeletal bone(29), but histological examination of matured HO is lacking. 
Figure 1. In the absence of ligands, FKBP12 binds to the ALK2 receptor to prevent signaling (A). When a ligand 
binds, FKBP12 dissociates form the ALK2 receptor. The ligand than promotes signaling of the receptor, including 
the SMAD 1/5/8 pathway (B). In the presence of Activin A, FKBP12 dissociates but signaling is inhibited (C). In 
the presence of a mutation at or near the GS domain of the ALK2 receptor, FKBP12 can no longer properly 
bind to the GS domain of the receptor. Therefore, in the absence of a ligand, there is leakage of ALK2 signaling 
(D). In addition, when a ligand binds to the mutated receptor, increased signaling is promoted (E). When Activin 
A binds the mutated receptor, the SMAD 1/5/8 pathway is activated (F).
Abbreviations: BMP = Bone Morphogenetic Protein; FKBP12 = FK506 binding protein 12; Act = Activin A; FOP 





Most knowledge on HO has been gathered through surgical excision of newly formed HO 
because of associated mobility restrictions. Whether this removed HO has already matured, 
is questionable. Therefore, the question remains whether matured HO is ‘normal’ bone. 
High-resolution peripheral quantitative computed tomography (HR-pQCT), a novel technique, 
might provide a solution. HR-pQCT is able to quantify bone geometry, density, and 
microarchitecture of both cortical and trabecular bone compartments as well as mechanical 
properties(31). This could give insight in for instance fracture risk of HO, as only limited data 
on fractures of HO are available (32).
Twenty percent of the flare-ups is not succeeded by HO formation, according to a 
questionnaire among five-hundred FOP patients(9). To date, it is not possible to distinguish 
a non-ossifying flare-up from an ossifying flare-up. In addition, it still is not possible to detect 
disease activity through laboratory tests. Biochemistry tests, including alkaline phosphatase, 
have shown to remain within normal limits in patients with FOP(33,34). Inflammatory markers, 
C-reactive protein and erythrocyte sedimentation rate, were found to be elevated early in 
the course of HO formation in non-genetic HO(35). Its value in FOP has been explored in case 
reports, but no clear relationship between inflammatory markers and a flare-up was seen(36). 
Furthermore, this survey among FOP patients also revealed subjective progression of HO 
in the absence of a flare-up(9). Both formation during fare-ups and maybe also this 
asymptomatic progression results in limited mobility of the affected joint(7,9). In addition, 
vital organ function may be affected as a result of HO that restricts thoracic movements. 
This most likely results in restrictive lung disease, as found by two cross-sectional studies 
among FOP patients (13),(14,37). The pulmonary function tests used in these studies, however, 
were only sufficient to suspect – and not confirm – a restrictive pulmonary function. The 
restrictive pulmonary function is thought to play a key role in the pathophysiology of 
premature death in FOP(12,13). Nonetheless, the natural course of the pulmonary function in 
FOP and its relation to the formation of HO is not known. 
Additional research is needed to understand HO development, progression, microstructure 
and complications. Invasive techniques are contraindicated in FOP, as they might trigger a 
flare-up(8). Insight needs to be obtained through non-invasive techniques. To understand 
the development and progression of HO, a method able to measure biological activity of 
bone is crucial. 
Imaging techniques to increase knowledge on HO
Molecular imaging techniques may be a way to characterise FOP disease activity non-
invasively. Amongst all molecular imaging techniques, positron emission tomography (PET) 
is especially interesting because of its high sensitivity and PET allows quantitative 
measurements of regional biological processes. For FOP, the tracer 18F-NaF is of interest, as 
it binds specifically to sites with active bone metabolism(38). More specifically, 18F-NaF binds 
to newly formed hydroxyapatite, where 18F-NaF replaces de hydroxyl group to form 
fluoroapatite(38). Using PET it is then possible to image (and measure) these binding sites. 
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In addition, the combined use with CT, also allows for precise localization of areas with 
increased uptake. Research is needed to explore the value of this technique for both 
development and progression of HO in FOP. As 18F-NaF PET/CT exposes a patient to radiation, 
it might not be the imaging technique of choice in the paediatric population. An alternative 
imaging technique might be magnetic resonance imaging (MRI). MRI makes use of a strong 
magnetic field, which enables the visualization of soft tissue, e.g. muscles(39). Despite the 
fact that MRI is not able to measure biological activity of bone, it may still have a role in the 
characterisation of disease activity, as one of the signs during a flare-up is oedema(40). Studies 
are needed to explore the value of MRI in FOP.
Aims and outlines of the thesis
The aim of the studies described in this thesis was to improve knowledge about development, 
progression, structure and complications of HO in FOP, and to investigate the effects of 
different kinds of trauma on disease activity and progression. As invasive techniques are 
contraindicated and blood markers to detect disease activity are not available, imaging 
techniques were used to study various aspects of the disease. 
The incompletely understood biological processes during a flare-up were investigated 
through sequential 18F-NaF PET/CT scans in chapter 2. Furthermore, in chapter 3 The 
natural course of HO in de absence of flare-ups was assessed by sequential 18F-NaF PET/
CT-scans. The potential value of MRI in assessing disease activity was investigated in chapter 
4 by comparing MRI with 18F-NaF PET/CT. 
Effects of surgery on flare-ups and the natural course of HO was evaluated in chapter 5. 
And, in chapter 6 the effects of local radiotherapy on local and systemic disease activity 
was assessed. 
 A new imaging modality, HR-pQCT, which can be used to describe geometry, density and 
microarchitecture of HO is presented in chapter 6. Finally, the natural course of pulmonary 
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18F-NaF PET/CT scan as an early marker of 
heterotopic ossification in fibrodysplasia 
ossificans progressiva




Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease with a progressive 
course characterized by episodically local flare-ups, which often but not always leads to 
heterotopic bone formation (HO).
Recently, we showed that 18F-NaF PET/CT may be the first tool to monitor progression of a 
posttraumatic flare-up leading to new HO, which was demonstrated in a patient with FOP 
who underwent a maxillofacial surgery.
This paper evaluates 18F-NaF PET/CT as a marker of FOP disease activity, comparing its use 
with other imaging modalities known in literature. In addition, the follow-up of a spontaneous 
flare-up in a 19-year old patient is presented showing high muscle 18F-NaF uptake in one 
defined part within the flare-up area after three weeks. During follow-up, 18F-NaF PET /CT 
scan revealed newly formed heterotopic bone but only in this previously active 18F-NaF 
region. In conclusion, increased muscle 18F-NaF uptake may predict future HO development 
in FOP patients. At present 18F-NaF PET/CT appears to be a sensitive imaging modality to 
serve as a noninvasive marker for bone formation and to monitor disease activity during 
flare-ups in FOP. 




Fibrodysplasia ossificans progressiva (FOP) is rare progressive genetic disease characterized 
by periodical flare-ups which predominantly present as swelling (93%), pain (86%), decreased 
movement (78%) and stiffness (72%)(1). Flare-ups may be induced by trauma, inflammation 
or may develop spontaneously(2). Most flare-ups lead to heterotopic bone formation (HO) 
with progressive loss of mobility. The development of HO follows a pattern through swelling, 
modification of affected skeletal muscle and connective tissue towards endochondral 
heterotopic bone formation leading to mature mineralized bone (3). However, it is estimated 
that about 20% of flare-ups may not proceed into HO formation and resolve completely, 
without loss of function (1). Due to incomplete insight in the total flare-up process and the 
lack of a marker of the disease, the spontaneous course of a flare-up is unpredictable. 
Recently, the Amsterdam FOP research group identified the 18F-NaF PET/CT scan as possible 
marker in predicting and monitoring HO formation in a very early phase of a flare-up, which 
was detected during a follow-up study after surgery in an FOP patient (4).
This article describes the use of 18F-NaF PET/CT as a new imaging modality to monitor disease 
activity during a flare-up in FOP, comparing the diagnostic value of 18F-NaF PET/CT with other 
imaging modalities. In addition, we present the first captured spontaneous course of a 
flare-up in an FOP patient by 18F-NaF PET/CT scanning. 
2. Imaging bone formation: the 18F-NaF PET/CT scan
Two imaging modalities are widely available for functional imaging of bone metabolism: 
bone scintigraphy using 99mTc-labeled diphosphonates (Tc-99m-hydroxydiphosphonate 
(99m-HDP) or methylene diphosphonate (99m-MDP)) and [18F] Sodium Fluoride (NaF) PET/
CT (5). 99mTc-labeled diphosphonates are widely available in general hospitals and are used 
with gamma cameras, yielding a conventional bone scintigraphy (5). Both tracers bind to 
sites of new bone formation and represents osteoblastic activity, but there are clear 
differences between both techniques.
Sodium fluoride labeled with [18F] (18F-NaF) is a positron emitter, which was first introduced 
for bone scanning in 1962 by Blau et al (5-7). In the last decade, the widespread availability 
of the hybrid PET/CT and its rapid increasing usage in patients with bone metastasis has 
led to a renewed interests in 18F-NaF PET/CT in spite of the higher costs compared to 99mTc-
MDP bone scanning. The intrinsic high spatial resolution of PET/CT systems offers superior 
image quality of [18F]fluoride PET images which is also of interest for the detection of osseous 
lesions such as heterotopic bone. Studies comparing [18F]fluoride PET with bone scintigraphy 
support the supremacy of 18F-NaF PET in detecting osseous lesions (8-10). The [18F]labeled 
fluoride is directly incorporated into bone matrix, due to the fluoride ion exchange with 
hydroxylgroups in the hydroxyapatite crystal of bone resulting in fluoroapatite (Ca10(PO4)6F2). 
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This process is closely related to active bone metabolism, as assessed by increased 
mineralization rate in histomorphometric studies in minipigs (11), thus providing a quantitative 
non-invasive estimate of bone formation (12). The 99mTc labeled diphosphonate uptake in the 
skeleton is attributed to chemical adsorption at the osteocyte lacunae and the mineralization 
front of the bone, but is not totally understood (7,13). 18F-NaF has a shorter half-life of 110 min 
and is therefore produced by cyclotron, compared to 6 h for 99mTc-labelled compounds. The 
delivery of 18F-NaF is not affected by protein binding, while protein binding of 99mTc-labeled 
diphosphonates increases over time from 25% to 50% at 4 h after the injection (14). The 
absent binding to serum proteins of 18F-NaF al lows a rapid single-pass extraction and fast 
clear ance from blood and soft tissue. Compared with 99mTc-labelled diphosphonates the 
bone uptake of 18F-NaF is twice as great (15). These characteristics of 18F-NaF combined with 
the higher resolution of PET scanners lead to shorter intervals and improved detection of 
bone lesions with 18F-NaF PET. Typically, a 2–4-hour interval between tracer injection and 
bone scintigraphy imaging is required. In contrast, 18F-NaF PET/CT imaging can be per formed 
within a 1 hour after injection. Notably, the length of the interval between injection of 18F-NaF 
and scanning affects semi-quantitative parameters such as standard uptake value (SUV), 
therefore the interval between injection and PET scanning should be standardized (12). 
Standardization facilitates comparison of quantitative parameters in serial 18F-NaF PET 
studies and may reduce the interindividual variation of [18F]fluoride uptake (16,17).
Recently the superiority of 18F-NaF PET/CT was shown in prostatic cancer (15,18), where earlier 
and more bone metastases were detected with sensitivity rates between 93-100% compared 
to 51% in bone scintigraphy (18,19); 18F-NaF PET/CT also correlated well with overall survival (18). 
3. Dosimetry and procedure of 18F-NaF PET/CT
18F-NaF is injected intravenously according to a procedure guideline for use of 18F-NaF PET/
CT (12,20). Typically this yields a dose of approximately 185 MBq 18F-NaF for an adult, however, 
lower doses are possible using modern 3D PET/CT scanners. Presently, we use a dose of 
1.2 MBq 18F-NaF /kg bodyweight in benign bone diseases (7,21). Accordingly, a dose of 100 
MBq 18F-NaF for an adult of 80 kg results in a radiation dose of 2.4 mSv. For comparison, a 
traditional bone scintigraphy performed after injection of 600 MBq 99mTc-MDP results in a 
dose of 3.4 mSv.
1h after injection of 18F-NaF whole body PET scans can be acquired from skull to feet, 
according to previously reported guidelines (12,20).
As in the presented case a Gemini TF PET/CT scanner (Philips, The Netherlands) may be 
used. Low-dose CT imaging (30 mAs) is used for attenuation correction (12). Activity in the 
region of interest (ROI) and the volume of interest (VOI) can be calculated using standard 
software ROI tool (as the Leuven ROI tool) to define the SUV. 18F-NaF uptake can be assessed 
both visually and quantitatively and be compared with reference areas, for example normal 
bone or soft tissue.. Heterotopic bone can be assessed on CT. 
18F-NaF PET/CT scan in FOP
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4. Quantification of 18F-NaF uptake
Visual assessment of [18F]fluoride images may be sufficient for diagnostic purposes, 
quantification is essential for monitoring response to treatment, as it enables objective 
assessment of changes in uptake over time (11,12). 
Various analytical approaches, varying from semi-quantitative indices such as SUV to full 
kinetic analysis of 18F-NaF kinetics, have been used to quantify fluoride uptake. A major 
advantage of SUV measurements is the simplified PET scanning protocol which only requires 
static 18F-NaF PET images, made for example 60 min after injection. Full kinetic analysis of 
18F-NaF kinetics yields robust and reliable estimates of 18F-NaF uptake, however, requires 
dynamic PET scanning with a length of up to 1 h, starting directly after 18F-NaF injection.
Recently, a high correlation between 18F-NaF SUV and full kinetic derived 18F-NaF Ki was found 
in a bone surgery study with correlation coefficients higher than 0.94 (11) Moreover, changes 
in 18F-NaF SUV after bone surgery correlated with those in Ki, indicating that changes of local 
bone metabolism could be monitored using the 18F-NaF SUV and a simplified PET scan 
protocol. However, this aforementioned PET study focused on the effects of local bone 
metabolic changes induced by bone surgery. Different therapies with medical interventions 
may have systemic effects upon bone metabolism and 18F-NaF kinetics (11). Therefore, 
separate studies with dynamic scanning in clinical practice and full kinetic modelling (using 
compartment modelling or Patlak analysis) are necessary to validate the application of the 
semi-quantitative indices, such as 18F-NaF systemic therapy in FOP patients (12).
5. 18F-NaF PET/CT follow-up in FOP: a case report
A 19-year old girl, diagnosed with FOP at the age of 6, experienced several flare-ups during 
that year. She suddenly noticed a painful increasing swelling extending to her total right 
upper leg. Three weeks later a 18F-NaF PET/CT showed markedly increased 18F-NaF uptake 
only at circumscriptive locations at the distal quadriceps muscle of the right leg. On the CT 
scan no evident HO was visible (Figure 1).
She was treated with high dosages of prednisolone almost from the onset until 2 months 
after the first 18F-NaF PET/CT scan in addition to nonsteroidal anti-inflammatory drugs for 
several months, after which the pain and swelling slowly decreased, finally resulting in a 
knee contracture and wheelchair dependence. After 8 months, when the flare-up had 
disappeared, a follow-up 18F-NaF PET/CT scan showed laterally disappeared and opposite 
a marked decreased muscle [18F]fluoride uptake at the right distal quadriceps (Figure 1). On 
the CT scan new maturing HO was visible only at the location of the muscle where the 18F-NaF 
PET/CT scan had been active before.
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Figure 1. Whole body 18F-NaF PET scan (skull excluded, maximum intensity projection) and 3D whole body 
CT scan of the FOP patient with suspected flare up in right leg (upper panel) with subsequent development 
of heterotopic bone on the second scan (lower panel). During a flare up with pain in the right upper leg, the 
18F-NaF PET showed markedly increased 18F-NaF uptake in the soft tissues of the distal part of the right upper 
leg. CT images showed no heterotopic bone in this region as indicated by the red arrow. The left upper leg 
showed no increased 18F-NaF uptake, despite clear heterotopic bone in the distal part of the left upper leg. 
Eight months later there is a marked reduction of 18F-NaF uptake in the right leg ,while the CT showed newly 
formed heterotopic bone in the right upper leg marked by the red arrow. The left leg showed unchanged 
heterotopic bone.




Despite tremendous progression in the understanding of biological features of FOP over 
the past two decades, the lack of fully understanding the natural flare-up course has 
hindered progress of clinical research, detection of a marker of disease activity and proper 
evaluation of new treatment options. This paper evaluates the use of 18F-NaF PET/CT scan 
as possible method to follow the course of a flare-up in FOP. Its findings support previous 
observations in an FOP patient where, after surgery, repeated 18F-NaF PET/CT scans could 
identify and quantify early foci of disease activity, which led to heterotopic ossification at a 
later stage (4).
The present 18F-NaF PET/CT findings show that in a spontaneous flare-up some areas may 
recover but other areas may progress to end-stage heterotopic ossification. This fate as well 
as the exact future HO location was detected by increased uptake of 18F-NaF 3 weeks after 
onset of the flare-up before HO could be detected on CT scan, but further research will be 
needed to investigate earlier time points. This indicates that 18F-NaF PET/CT could potentially 
be used for early recognition of an active ossification process prior to bone formation at 
least 3 weeks after the first signs of a flare-up. Therefore, in new FOP drug trials, 18F-NaF 
PET/CT may become a useful tool for monitoring early effectiveness of drugs and, as such, 
support the guidance of therapy. 
Previously, bone scintigraphy has been used in FOP but only during differential diagnosis 
(22,23). In general, a bone scintigraphy can be helpful for detection of HO but theoretically, 
18F-NaF PET has a better imaging characteristics compared with the traditional bone 
scintigraphy, which may explain the lack of sensitivity of the bone scintigraphy for detection 
of the early phase of a flare-up (22). A CT scan provides valuable information regarding the 
presence and extension of HO, however, a CT cannot detect the early biological process 
and active bone metabolism. MRI and other PET tracers such as [18F]fluordeoxyglucose (FDG) 
PET may be used for early detection of inflammation, but are not bone specific and therefore 
may not be able to distinguish between flare-up induced HO or other inflammatory 
responses (12,24). Nevertheless, both MRI and 18F-FDG PET may still be of additional values, 
especially in the very early phase of a flare-up, as it is not known yet whether 18F-NaF can 
detect HO activity in the first 3 weeks after onset. Moreover, these imaging techniques may 
provide supplemental information about the inflammatory process, which is independent 
of or prior to possible bone formation. 
 18F-NaF uptake in the bone reflects increased bone formation, including any process that 
increases the exposed bone crystal surface at early stages (5). As a consequence, this imaging 
technique is increasingly being used to detect bone and bone related disorders, joint conditions 
such as osteoarthritis (21), osseous metastases of a variety of cancers (16), lytic and early marrow-
based metastases when accompanied by minimal, reactive osteoblastic changes (15) and to 
evaluate treatment efficacy as recently successfully was shown in multiple myeloma (12,25). In 
future this technique might also help to understand the progressive course in some FOP 
patients who do not experience clinical flare-ups, but nevertheless show increasing HO (1).
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Interestingly, also in myositis ossificans circumscripta, which is caused by a local unusual 
reactive process of mesenchymal stem cells in muscles mostly secondary to a trauma or 
inflammatory process, a 35% rate of spontaneous resolution has been reported (26) .This 
emphasizes that the recovery from an initial inflammation phase in FOP may occur 
independent from the underlying genetic cause and in this phase mesenchymal cells can 
convert to support normal muscle cells again. Serial 18F-NaF PET/CT might support the 
understanding of the different phases of a flare-ups in the future. Present limitations of the 
use of 18F-NaF PET/CT in FOP are the small number of FOP patients investigated so far, the 
variable course of the disease, which needs more follow-up data of different flare-up 
symptoms and of patients who are affected differently. In addition, more follow-up will be 
needed to assess the possible incidence of false positive diagnoses, which may be due to 
osteochondromas or osteoarthritis. However, as the exact location and characterization 
might be detected with CT, this may rule out suspected other diseases or non-suspicious 
locations. 
In conclusion, 18F-NaF PET/CT appears to be a promising imaging modality that may 
potentially be useful for early recognition of new HO formation in FOP. Based on its 
quantitative properties, 18F-NaF PET/CT could also provide a means for monitoring 
effectiveness of drugs early in during therapy, for instance in new FOP trials.
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fibrodysplasia ossificans progressiva:  
an 18F-NaF PET/CT study




Fibrodysplasia ossificans progressiva (FOP) is a rare, autosomal dominant disorder 
characterized by heterotopic ossification (HO) in muscles, ligaments and tendons. Flare-ups 
often precede the formation of HO, resulting in immobilization of joints. Due to progression 
of the disease without signs of a flare-up, co-existence of a chronic progression of HO has 
been postulated, but conclusive evidence is lacking. Recently, it has been shown that 18F-NaF 
PET/CT is able to identify early ossifying disease activity during flare-ups. Therefore, the 
purpose of the present study was to assess whether 18F-NaF PET/CT might also be able to 
identify the possible presence of chronic progressive HO in FOP.
A total of thirteen 18F-NaF PET/CT scans from five FOP patients were analysed. Scans were 
acquired over a period of 0.5 to 2 years. Volumes of HO and standardized uptake values 
(SUV) were obtained based on manual segmentation of CT images. SUVpeak values, defined 
as the average SUV value of a 1 mL sphere containing the hottest voxel pixels, were 
obtained.
Two out of five patients experienced ≥1 active clinical flare-ups at the time of the 18F-NaF 
PET/CT scan. In addition, in four out of five patients, serial scans showed radiological 
progression of HO (3 to 8 cm3), as assessed by CT volume, in the absence of a clinical flare-
up. This volumetric increase was present in 6/47 (12.8%) of identified HO structures and, in 
all cases, was accompanied by increased 18F-NaF uptake, with SUVpeak ranging from 8.4 to 
17.9. 
In conclusion, HO may progress without signs of a flare-up. 18F-NaF PET/CT is able to identify 
these asymptomatic, but progressive HO lesions, thereby demonstrating the presence of 
chronic activity in FOP. Consequently, future drugs should not only target new HO formation, 
but also this chronic HO progression. 




Fibrodysplasia ossificans progressiva (FOP) is a rare, autosomal dominant disease, which is 
characterized by heterotopic ossification (HO) of connective tissue (1-3). Flare-ups, 
characterized by local swelling, pain, warmth, impaired movement and stiffness, often 
precede new HO formation (3,4). As a result of these new HO lesions, mobility in joints is 
gradually impaired and many patients become immobilized at an early age (1). Previously, 
progression of existing HO lesions has been reported, but it is unknown whether these 
progressions occurred in the presence or absence of a clinical flare-up (5,6). In a recent 
questionnaire distributed among five hundred FOP patients, however, nearly 50% of the 
responders reported progression of their disease without flare-up symptoms(4). In addition, 
in ACVR1R206H knock-in mice, HO progression has been confirmed even weeks after a trauma 
induced flare-up, suggesting the presence of a chronic component of the disease (7,8). 
Previously it has been shown that ossifying flare-ups can be identified and visualised using 
18F-NaF PET/CT-scan (9,10). 18F-NaF (i.e. labelled sodium fluoride) binds to the surface of newly 
formed hydroxyapatite, a crystal formed by osteoblasts during bone mineralization, based 
on the exchange of [18F] and hydroxyl-ions (11,12). The purpose of the present study was to 
assess whether this imaging technique is also able to identify asymptomatic progressive 
lesions, if present. 
2. Method
FOP patients, of the FOP expertise center of the Amsterdam UMC, for whom two or more 
18F-NaF PET/CT-scans were available were included. Images were obtained for either annual 
follow-up of the disease, (new) complaints or suspicion of a flare-up. Clinical information 
on both the presence of a flare-up and other complaints were recorded. The Medical Ethics 
Review Committee of the Amsterdam UMC, Vrije Universiteit Amsterdam, approved the 
study and all patients signed informed consent for using their data in the present study. 
All 18F-NaF scans were performed at the Amsterdam UMC, Vrije Universiteit Amsterdam. 
Scans were acquired using a Gemini TF-64 PET/CT scanner (Philips Medical Systems, Best, 
The Netherlands). Low dose whole body CT scans were acquired at 120 kV with a tube 
current ranging from 30 to 60 mAs. The 18F-NaF dose was adjusted to weight (e.g. 83 MBq 
18F-NaF for a 70-79 kg patient). Scan time per bed position was 2 min. 
PET and CT images were visually assessed to identify HO. After identification, images were 
segmented manually using the software tool “Accurate”, which previously has been described 
in more detail (13,14). The tool was used to identify HO volumes of interest (VOIs) and derive 
corresponding PET and CT values (Standardized uptake value (SUV) and volume, respectively). 
SUVpeak was defined as the average SUV of a 1cm
3 sphere, centered on the hottest voxel. 
 A Hounsfield unit cut-off of 80 was used to separate bone from other tissues. This cut-off 
was found to exclude muscle and to include all (immature) bone in the bone segments. All 
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segmentations were performed by one reviewer, but in all patients, a predefined number 
of randomly chosen HO were manually segmented by a second, independent reviewer. 
Both reviewers were blinded to both SUVs and volumes until segmentation of all successive 
scans were completed. 
Reference SUV values were established to define a cut-off value for the distinction between 
normal and increased 18F-NaF uptake. Since reference SUV values were not available for the 
skeleton of FOP patients, several potential reference tissues were explored (caput femori, 
lumbar vertebral body and the supra-acetabular region). The most stable region was chosen 
as a fixed reference for all analyses. SUVpeak values exceeding two standard deviations (SD) 
of the normal skeleton were considered divergent.
Lesions were found asymptomatic when patients did not report a flare-up or physical 
complaints for that specific region within the last three months before the first scan. For 
the follow-up scans, lesions were found asymptomatic if patients did not report any 
complaints in that specific area during the course of the study.
Statistical analyses were performed using SPSS Statistics for Windows, (IBM, version 24.0, 
Armonk). Independent T-tests and Mann-Whitney U tests were used to test significance 
between progressive and non-progressive lesions. The Spearman test was used to assess 
correlations. 
3. Results
In total 5 patients, treated at the FOP expert center of the Amsterdam UMC, Vrije Universiteit 
Amsterdam, were included in the analysis. Four patients had the classical mutation 
(c.617G4A; p.R206H); one patient a variant (c.619C>G, p.Q207E). In these five individuals, a 
total of 13 18F-NaF PET/CT scans were acquired in the course of 0.5 – 2 years. Three patients 
were evaluated based on two 18F-NaF scans. For one patient three scans were available and 
for one patient four (Table 1).
Bone was considered a reliable reference when free of HO and with stable SUV throughout 
the course of the consecutive 18F-NaF scans. The supra-acetabular region showed stable 
SUV throughout all (including consecutive) 18F-NaF scans and, therefore, was considered to 
be a reliable reference region. The average SUVpeak for both left and right supra-acetabular 
regions was 5.5 ± 1.4. Consequently, HO lesions with SUVpeak values exceeding two standard 
deviations of the reference (SUVpeak ≥8.4) were considered to be metabolically active. Lesions 
with SUVpeak beneath this limit were considered to have normal metabolic activity. 
All HO lesions were manually identified and segmented. After manual segmentation by one 
reviewer (EB), a second reviewer (BT, musculoskeletal and emergency radiologist) manually 
segmented 10 of 52 (19.2%) randomly selected HO structures. A comparison of obtained 
volumes and SUVs showed a near-perfect correlation between both observers (intraclass 
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correlation coefficient = 0.99). Based on this inter-observer variability, volumetric changes 
of >3 cm3 were considered meaningful (mean difference 1cm3, standard deviation 0.5 cm3) 
Among the 5 individuals, 52 different HO structures were identified of which 47 structures 
were not affected by a flare-up. Three flare-ups, in two patients, were present at baseline. 
All regions affected by a flare-up were in a region in which initially no HO was present. The 
total number of HO lesions ranged from 7 to 16 per patient, with an average of 10. The total 
volume of HO varied from 139 – 1140 cm3 per patient, based on the last obtained scan of 
each patient. 
Flare-ups were present in two out of the five patients during the course of the study. Flare-
ups were identified based on patient’s symptomatology. All flare-ups were followed by HO 
formation. In patient 4 a flare-up was triggered by surgery of the jaw, resulting in a SUVpeak 
that, at some stage, exceeded 25. 18F-NaF PET showed normalization (SUVpeak <8.4) of uptake 
18 months after surgery. For all other flare-ups (the right loin, right groin and right upper 
leg) no trigger was identified and these flare-ups were therefore considered idiopathic. All 
flare-up regions showed a SUVpeak between 21 and 48 (Figure 1). These flare-ups have been 
described previously by Eekhoff et al. (9,10). No new HO lesions appeared without a flare-up. 
However, 6 out of 47 (12.8%) HO structures, not involved in a flare-up, showed a volumetric 
Table 1. Patient characteristics 







1 41 ♀ R206H 1 -
2 10
2 17 ♂ R206H 1 -
2 20
3 23 ♀ R206H 1 -
2 6




5 19 ♀ Q207E 1 - m. psoas
2 5 m. quadriceps, 
femur-pubis region
3 13
* Age at time of the first 18F-NaF PET/CT scan 
** Genetic analysis performed at het Amsterdam UMC, location VUmc, the Netherlands. 
*** Time between first and successive scan
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progression by CT during follow-up. These 6 progressive but asymptomatic HO lesions were 
found in 4 out of 5 patients One patient showed progression in 3 out of 16 heterotopic 
lesions: the right femur pubis and both sides of the thoracic region. The other 3 patients all 
showed one progressive HO lesion. In two patients, these HO lesions were located in the 
right thoracic region and for one patient paravertebral. (Figure 2). Volumetric expansion 
ranged from 3 to 8 cm3. All 6 progressive lesions were accompanied by increased 18F-NaF 
uptake. After normalization of 18F-NaF uptake (SUVpeak ≤8.4), lesions did not show further 
volumetric expansion (Figure 3). Progressive lesions were significantly larger than non-
progressive HO lesions (Mann-Whitney U test, p<0.05). Multiple sites with increased 18F-NaF 
uptake were identified within all progressive HO lesions. Increased 18F-NaF uptake was seen 
where HO adjoins the skeletal bones (6/6). For several of these structures (3/6) however, 
uptake was also present in regions where the HO did not adjoin skeletal or other heterotopic 
lesions. The extent of progression did not correlate with SUVpeak (Spearman r = 0.657, p = 
0.156). All other HO lesions did not show increased 18F-NaF uptake. Lesions without increased 
18F-NaF uptake showed no progression on successive CT-scans
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Figure 1. Consecutive SUVpeak values obtained from 18F-NaF PET/CT scans for regions in which patients 
experienced a flare-up. For all regions SUVpeak exceeded 25 in the course of the flare-up. The flare-up in the 
left and right jaw (patient 4, grey lines) was triggered by a surgical procedure. For the other flare-ups (patient 
5, black lines) no triggers were identified. 
Abbreviations: SUV = standardized uptake value, (l) = left, (r) = right
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Figure 2. Axial images of progressive heterotopic bone lesions with visibly increased 18F-NaF uptake. These 
progressive lesions all had increased sodium fluoride uptake (red circles in images), defined by a SUVpeak >8.36. 
Volumetric values and SUVpeak values for each heterotopic lesion are shown in Figure 3.
A. Paravertebral region, patient 2
B. Right femur pubis region, patient 3
C. Right thoracic region, patient 3
D. Left thoracic region, patient 3
E. Right thoracic region, patient 4
F. Right thoracic region, patient 5 
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Figure 3. Volumetric increase and SUVpeak values for each progressive lesion identified by successive 18F-NaF 
PET/CT-scans. Progressive heterotopic bone lesions were accompanied or preceded by an increased 
sodium fluoride uptake, reflecting active bone metabolism. Active bone metabolism represents progression 
of heterotopic ossification. Patients did not experience any complaints or flare-ups in these regions three 
months before the first scan and during the entire course of this study. After normalization of 18F-NaF uptake 
(SUVpeak <8,4: panels A, E and F), no further progression was identified.
Abbreviations: SUV = standardized uptake value. 
A. Paravertebral region, patient 2hn
B. Right femur pubis region, patient 3
C. Right thoracic region, patient 3
D. Left thoracic region, patient 3
E. Right thoracic region, patient 4
F. Right thoracic region, patient 5 




The main finding of the present study is that HO in FOP patients may progress without any 
clinical signs. In 4 out of the 5 FOP patients studied, one or more asymptomatic HO lesions 
showed volumetric progression. These progressive lesions were all detected by increased 
18F-NaF uptake on PET/CT scans, confirming the existence of an asymptomatic chronic stage 
in FOP that is not related to the presence of a clinically apparent flare-up.
Ongoing progression could be identified for a maximum period of 7 months. As the 18F-NaF 
PET is a fairly new imaging technique to visualize FOP, successive scans with a relatively 
short interval of only 5 patients were available for analysis. Also, because of the limited 
availability of 18F-NaF PET/CT scans (due to costs and feasibility) further data are needed to 
characterize the time course in this chronic stage. Especially for future treatments, this time 
course would be key to judge the efficacy of drugs on this chronic stage. It is likely that 
chronic stage lasts very long, as a lesion that has been active for 13 years has already been 
reported (10). This 13-year active lesion was identified by Tc-99m methylene diphosphonate 
[99mTc]MDP bone scintigraphy. Bone scintigraphy is still widely used to detect osteoblastic 
activity. Compared with [99mTc]MDP bone scintigraphy, however, the 18F-NaF PET/CT has 
higher sensitivity and higher spatial resolution. In addition, the quality of the 18F-NaF PET/
CT images is better due to lower plasma protein binding and, therefore, higher uptake in 
bone. Also, 18F-NaF PET/CT images can be quantified more easily (15,16). As both techniques 
expose the patient to radiation(15), there is a limitation of scans allowed for research ends. 
For clinical purposes, however, 18F-NaF PET/CT-scans, scans are allowed as long as it is 
between reasonable limits and in the benefit of the patient.
In 4 out of 5 patients the classical mutation in the ACVR1 gene (c.617G>A, p.R206H) was 
identified. In one patient, however, a variant of the FOP mutation [c.619C>G, p.Q207E] was 
seen, although the phenotype was similar to that of the patients with the classical mutation. 
This variant mutation has been identified and reported for two other patients. Haupt et al. 
described a patient with this variant mutation that led to a phenotype similar to the classical 
mutation (17). The other patient, described by Kaplan et al, also showed atypical features 
including a failure to thrive, which, however, was not attributed to this mutation (18). In the 
present study no atypical features were observed in any of the patients. 
Only one patient, patient 1, showed neither active flare-ups nor progressive HO lesions 
during 11 months. In this patient, the 18F-NaF PET/CT scans were obtained because of 
multiple comorbidities (e.g. chronic osteomyelitis of the leg and cerebrovascular accidents). 
The effect of comorbidities on the FOP activity is not known yet. Follow-up scans of this 
patient, might reveal whether a chronic stage is also present in this patient. 
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SUVpeak was significantly lower in the asymptomatic chronic lesions (range 8.5-17.9) compared 
with the symptomatic acute lesions (range 21.3 – 48.7) (Mann-Whitney U test, p <0,05), 
making it not only possible to identify these chronic lesions using the 18F-NaF PET/CT-scan, 
but also to distinguish them from active flare-ups. As no flare-up had occurred 3 months 
prior to and during the entire course of the study at the sites of the chronic lesions, it is not 
likely that this progression is due to a residuum of a flare-up locally. 
18F-NaF PET/CT is best known for its role in assessing metastatic bone lesions in oncology 
(19). In addition, it has also shown great promise in visualizing early ossifying flare-ups in 
patients with FOP (9,10). Although SUVmax is often used based on its simplicity and because it 
is operator independent (20), it can be affected by noise as its value is based on a single voxel 
(0.064mL) (21,22). SUVpeak is based on a larger region (1.0 mL) and therefore least affected by 
noise (23). As notable growth will involve multiple voxels, SUVpeak was used in the present 
study. SUVpeak also is more robust, reproducible and reliable measure than SUVmax 
(20,22). 
Although, Cremin et al. described HO progression after a flare-up using plain radiographs 
(5), the present FOP data are unique, as no asymptomatic heterotopic lesions have been 
followed quantitatively using 18F-NaF PET/CT. In contrast to X-rays, 18F-NaF PET/CT scan allows 
early identification of progressive HO by uptake of 18F-NaF.
Results of this study are potentially important for future trials, as they indicate that a chronic 
component in FOP should be taken into account. Future drugs should not only target HO 
formation after a flare-up, but also chronic HO progression. 
In conclusion, FOP is known for its periodical flare-ups followed by HO formation. However, 
a substantial fraction of HO lesions progresses in the absence of any clinical signs. 18F-NaF 
PET/CT is a promising imaging modality, as it can visualize ossifying flare-ups even before 
HO has formed and therefore it may be used to monitor progression of existing HO. 
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Using 18F-NaF positron emission tomography (PET) it is not only possible to identify the 
ossifying potency of a flare-up, but also to identify an asymptomatic chronic stage of 
fibrodysplasia ossificans progressiva (FOP). The purpose of this study was to investigate the 
diagnostic role of a more widely available imaging modality, magnetic resonance imaging 
(MRI), which is of special interest for studies in paediatric FOP patients.
MRI and 18F-NaF PET/CT images at time of inclusion, and subsequent follow-up CT scans of 
4 patients were analysed retrospectively. Presence, location and intensity of oedema 
identified by MRI were compared with activity on 18F-NaF PET. Occurrence or progression 
of HO was examined on the follow-up CT-images.
Thirteen different lesions in various muscle groups were identified: 5 lesions with only 
oedema; 5 lesions with both oedema and increased 18F-NaF uptake; 1 lesion with only 
increased 18F-NaF uptake and 2 lesions with neither oedema nor uptake of 18F-NaF. Mild 
oedema, found in 3 lesions, was present at asymptomatic sites which did not show increased 
[18F] NaF uptake, nor progression of HO on consecutive CTs. Moderate oedema was found 
in 3 symptomatic lesions, with increased 18F-NaF on PET and progression of HO on CT. Severe 
oedema was identified in 4 lesions. Interestingly, 2 of these lesions did not develop HO 
during follow-up, while one of these two even gave obvious symptoms of a flare-up. 
MRI can identify whether symptoms are the result of an acute flare-up by the presence of 
moderate to severe oedema. The occurrence of severe oedema on MRI was not always 
related to an ossifying lesion. The additional diagnostic value of MRI requires further 
investigation, but MRI does not seem to fully replace the diagnostic characteristics of 18F-NaF 
PET/CT in FOP. 




Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease leading to ankyloses 
due to excessive heterotopic bone formation in connective tissue (1-3). This progressive 
autosomal dominant disorder is characterized by periodical flare-ups (2,4,5). A flare-up is 
thought to start with an inflammatory process in muscles, tendons and ligaments. Flare-ups 
often, but not always, result in formation of heterotopic ossification (HO) (5). Nowadays, a 
flare-up is defined by its symptoms, the most prominent ones being swelling and pain (5). 
Due to the lack of (blood)markers, a flare-up is still a clinical diagnosis. Using 18F-NaF PET/
CT (positron emission tomography / computerized tomography), however, it has become 
possible to identify which of these flare-ups will lead to HO (6,7). Recently, it was shown that 
18F-NaF PET/CT can also identify asymptomatic chronic progression of existing HO, based 
on relatively lower but still increased 18F-NaF uptake (8). Using this new marker of active and 
chronic FOP disease, it has become possible to investigate the diagnostic role of other, more 
widely available imaging modalities such as magnetic resonance imaging (MRI). The absence 
of ionizing radiation makes this technique especially interesting for the paediatric FOP 
population.
MRI provides high soft-tissue contrast and is able to detect oedema, a potential marker of 
inflammatory stages in FOP (9-12). MRI is currently used in FOP to evaluate the presence of 
oedema early in flare-ups(10). Whether the two stages of FOP, i.e. active flare-ups and 
asymptomatic chronic FOP disease, have similar inflammatory patterns and corresponding 
MRI signals is not yet known. 
A few FOP case reports have described hyper-intense foci on T2-weighted images during 
flare-ups (9,11,13-15), but whether these hyper-intense foci on MRI led to formation of HO was 
not investigated. Nevertheless, In R206H Acvr1 knock-in mice, it was shown that sites of HO 
formation coincided with hyper-intense T2 signals. Once HO was formed, the signal subsided. 
In this animal model, MRI T2-signal was in accordance with 18F-NaF PET-signal(16). For human 
FOP patients, however, it is not known whether oedema on MRI can distinguish between 
ossifying and non-ossifying flare-ups, as well as between active and asymptomatic chronic 
FOP disease, as in the case for 18F-NaF PET/CT (8). Therefore, the aim of this study was to 
assess whether MRI can identify different stages of FOP. Although ossifying and non-ossifying 
flare-ups are clinically indistinguishable(5), it could be possible that the severity of oedema 
on MRI may predict the fate of a flare-up. In addition, assumeing that HO formation is always 





Adult FOP patients, under the care of the FOP expertise centre of the Amsterdam UMC, in 
whom both MRI and 18F-NaF PET/CT scans were performed, were included. MRI and 18F-NaF 
PET/CT scans had to be acquired within 14 days of each other, to allow for reliable 
comparisons. In addition, a follow-up CT scan, obtained at least six months after the initial 
scans, had to be available to assess whether HO had formed. Any additional MRI and 18F-NaF 
PET/CT-images available within the studied timeframe, were included in the analyses as 
well. Patients were asked to sign a consent for analysing and publishing their data 
anonymously. The study had been approved by the Medical Ethics Review Committee of 
Amsterdam UMC.
MRI was acquired on a 1.5T system (Signa Excite HDxt, GE Healthcare, Milwaukee, WI, USA) 
and a 3T system (Vantage Titan, Canon Medical Systems, Otawara, Japan). MRI scans were 
obtained either at an annual follow-up or for a suspected flare-up. Although different 
imaging protocols were used, T2 STIR (Short-TI Inversion Recovery) acquisitions were 
available for all MRI scans included. MRI parameters are presented in table 1 of the 
supplemental material. The intensity of oedema was graded on a semi-quantitative scale: 
absent, mild, moderate or severe (17-19). Two reviewers (BT, musculoskeletal radiologist at 
Amsterdam UMC and EB) independently graded the degree of oedema. BT was not involved 
in clinical care of the FOP patients at the time of image acquisition. Both reviewers were 
blinded to clinical data. To limit bias, the review of 18F-NaF PET and CT data was performed 
at least two months apart from the review of the MRI-images. The reviewers were instructed 
to grade oedema in accordance to Davis et al., a juvenile dermatomyositis scoring system 
for the MRI (17). Discrepancies were resolved by consensus.
18F-NaF PET/CT scans were obtained using a Gemini TF-64 PET/CT scanner (Philips Medical 
Systems, Best, The Netherlands). Patients were scanned from the top of the skull to the 
toes. The 18F-NaF dose was adjusted to weight (e.g. 83 MBq 18F-NaF for a 70-79 kg patient) 
and a scan time of 2 minutes per bed position was used. Uptake of 18F-NaF was considered 
increased for chronic lesions when SUVpeak exceeded 8.4 
(8). The method used to analyse 
18F-NaF PET/CT has been described in our previous paper more extensively(8). For flare-ups, 
no SUVpeak cut-off was available, but in practice it is assumed to be 2-3 times higher than 
that for a chronic lesion(8). Whole body CT-images were acquired at 120 kV with a tube 
current varying between 30-60 mAs. CT-volumes were obtained for each heterotopic lesion 
identified. Two reviewers (EB and BT) independently analysed 18F-NaF PET/CT images. Again, 
discrepancies were resolved by consensus.
Follow-up low dose whole body CT scans were also acquired at 120 kV with a tube current 
varying between 30 and 60 mAs. The volumes of the various lesions were analysed to assess 
whether these lesions progressed during the course of this study. The same two reviewers 
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(EB and BT) independently analysed CT images. Discrepancies were resolved by consensus.
Clinical data were evaluated separately to assess clinical signs of the patients at the time of 
MRI, 18F-NaF PET/CT and follow-up CT scans. A flare-up was assessed and confirmed by the 
physician based on the presence of symptoms e.g. swelling, redness, pain. When HO 
progressed in the absence of any clinical symptoms at that site in the last six months it was 
considered chronic. 
Inter-observer correlation was assessed using Cohen’s kappa. Spearman’s rho was used for 
correlation between oedema grading and SUVpeak values. All statistical analyses were 
performed using IBM SPSS Statistics for Windows, version 24.0.
3. Results
Four FOP patients were included as for all four MRI, 18F-NaF PET/CT and at least one follow-
up CT scan were available. In fact, for the assessment of these four patients, eight MRI-scans, 
six 18F-NaF PET/CT-scans and four follow-up CT-scans were available.
Using MRI, 10 different oedematous lesions were found. Increased sodium fluoride uptake 
was found in only five and clinical signs of a flare-up were present in only six of the lesions 
identified by MRI (table 2). Using 18F-NaF PET/CT, six lesions showed increased uptake of 
18F-NaF. In five, oedema was present and also for five of those six 18F-NaF positive lesions 
patients complained of discomfort. six sites were identified solely by discomfort which was 
recognized by the patient as a flare-up. In four of the six symptomatic sites oedema was 
demonstrated by MRI. Only three of these six symptomatic sites showed increased 18F-NaF 
uptake on PET. Combining the lesions and sites found with MRI, 18F-NaF PET/CT and clinical 
signs, 13 distinctive sites were identified and analysed further. 
Table 1. Demographic characteristics of the included patients
Sex Agea Flare-upb Medicationc
1 ♀ 19 m. psoas, m. iliapsoas Prednisolon, ibuprofen
2 ♀ 23 - -
3 ♀ 23 Flare-up bilateral jaw Prednisolon, Ibuprofen
4 ♂ 20 Suspicion flare-up jaw Naproxen 
a Flare-up during the course of the study
b Age at time of the first MRI
c Medication taken during the course of the study. This may have been temporarily or continuously.
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Of the 10 oedematous lesions identified by MRI, oedema was classified as mild in three, 
moderate in three and severe in four lesions (table 2). There was a good correlation in 
scoring of oedema between the two independent reviewers (Cohen’s κ = 0.7; p= <0.05). 
None of the three mildly oedematous lesions showed progression of HO. There was no 
increased uptake of 18F-NaF, nor were there any clinical signs reported at these sites. In 
contrast to these mild lesions, all 3 lesions with moderate oedema were followed by HO 
progression. In addition, all showed increased 18F-NaF uptake and were accompanied by 
signs of a flare-up. Interestingly, two of the four sites with severe oedema did not develop 
HO. Although one of these lesions was accompanied with common flare-up symptoms, such 
as swelling and pain (figure 1A-C), it did not show increased activity on 18F-NaF PET. 
Interestingly, the adjacent muscle showed moderate oedema (figure 1A-C), which did result 
in HO development. 18F-NaF uptake was increased only in the muscle group that showed 
HO development (Figure 1D-F). Figure 1 shows the course of the oedema over 11 months, 
with great differences in oedema intensity after one month. After 11 months, the oedema 
had completely resolved. 
The other lesion with severe oedema was a clinically asymptomatic lesion. Again, the 18F-NaF 
PET scan did not show increased uptake of 18F-NaF in this area and the successive CT-scan 
did not reveal any HO progression of that particular region. 
Table 2. Identified muscle-(groups) by either complaints, oedema on MRI or increased 18F-NaF uptake on PET/CT
Muscle(group) MRI oedema 18F-NaF PET 
(SUVpeak)
Clinical signs Progression 
HO volume 
Jaw dextra None 4.1 Present No
Jaw sinistra None 2.3 Present No
Paracostal area dextra None 9.8 Absent Yes
M. psoas sinistra Mild 5.4 Absent No
M. glutei dextra Mild 1.4 Absent No
M. glutei sinistra Mild 2.2 Absent No
Jaw dextra Moderate 28.5 Present Yes
Jaw sinistra Moderate 26.4 Present Yes
M psoas dextra Moderate 32.5 Present Yes
M. Iliapsoas dextra Severe 3.9 Present No
Mm. Adductores dextra Severe 48.7 Present Yes
M. Quadriceps dextra Severe 41.9 Present Yes
M. gluteus maximus Severe 2.1 Absent No
Abbreviations: MRI = Magnetic resonance imaging; PET = Positron Emission Tomography; HO = Heterotopic 
ossification; m. = musculus
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One site was identified by increased uptake of 18F-NaF on PET, but did not reveal any 
oedema. The patient denied having had complaints in that area for at least six months. The 
follow-up CT-scan, however, revealed progression of HO in that particular lesion. Taking all 
oedematous lesions into account, 18F-NaF SUVpeak showed no significant correlation with 
oedema intensity (Spearman’s ρ= 0.4; p=0.222 ). In addition, the volume increase of new 
lesions or with HO progression was weakly related to the intensity of the oedema as found 
by MRI (Spearman’s rho = 0.6; p=0.244)
Figure 1. Coronal MRI T2 weighted STIR images are shown of a patients with multiple flare-ups. Starting in the 
loin (A+D), later also the groin (B) and upper leg (C+E). T in months. A and D; T = 0. Clinically a flare-up in the 
pelvic area with pain and swelling of the entire right loin. MRI (plane A) showed moderate and severe oedema 
of the musculus psoas dextra (white arrows) and the musculus iliacus dextra, respectively. Also, the musculi 
adductores (red arrows) showed moderate oedema, even though no clinical signs were noted. The MRI 
showed also an area of non-specific mild oedema (white circle). 18F-NaF PET showed increased high uptake 
of tracer in the psoas muscle, mild uptake in the mm. adductores and no uptake in the iliopsoas muscle. B; 
T = 1. Oedema at both the musculus psoas and musculus iliacus diminished, to mild and moderate oedema 
respectively. Oedema intensity at the musculi adductores increased to severe, the patient now reported flare-
up symptoms at the groin too. The mild oedema seen in plane A resolved, no calcifications were noted. C and 
E; T = 11. Oedema at the psoas muscle, iliacus and adductor muscles is completely resolved, but new oedema 
formed in the quadriceps muscle(plane C). High 18F-NaF uptake in the quadriceps (plane E). F; T = 21. Low dose 
whole body CT showed HO in the psoas muscle, HO at the site of the adductor muscles (red arrow) and in the 
quadriceps muscle. No HO formed in the iliopsoas (blue arrow). 
Abbreviations: MRI = magnetic resonance imaging; NaF = sodium fluoride; PET = positron emission 




Apart from lesions identified by MRI and 18F-NaF PET, two sites were analysed because of 
clinical complaints suggesting a flare-up. MRI did not show oedema at either site, neither 
did 18F-NaF PET show increased uptake of 18F-NaF. In addition, there was no HO progression 
on the subsequent CT-scan. The patients’ complaints resolved within a couple of weeks 
without intervention, suggesting a different underlying mechanism. Taking 18F-NaF PET/CT 
as the golden standard, MRI had a sensitivity of 83% and a specificity of 29% to detect FOP 
activity leading to HO formation. Positive and negative predictive values of MRI in this study 
were 50 and 66%, respectively. 
The maximum duration of oedema seen in this study was five months. No flare-ups were 
found in which oedema was absent whilst HO was being formed. In one case (figure 1 A 
and D), 18F-NaF PET/CT did not reveal increased uptake of the tracer yet, whereas the MRI 
obtained 14 days later, did show moderate oedema. Later in the course of this lesion, 
oedema progressed to severe and 18F-NaF uptake was found. 
4. Discussion
The aim of this study was to determine the diagnostic value of MRI in FOP by comparing it 
with the recently validated marker of disease activity: the 18F-NaF PET/CT. Results were 
evaluated using follow-up CT and clinical data. In this small series of patients, an active 
flare-up was always accompanied by moderate to severe oedema on MRI. Interestingly, 
presence and severity of oedema did not always correlate with the ossifying potency of the 
involved muscle location. In addition, the chronic stage in FOP was not associated with 
oedema on MRI. Finally, mild oedema was seen at several sites, but this was not related to 
18F-NaF PET/CT, HO nor to clinical complaints. 
The finding that all flare-ups were accompanied by oedema on MR-imaging is in line with 
five case reports (9,11,13-15). In these case reports, often MRI was used to evaluate soft tissue 
swelling in an, at that time, undiagnosed child with FOP. As the course of these flare-ups 
was not followed, both implications and diagnostic value of MRI remained unclear. The 
present study shows a sensitivity of 83% of MRI as compared with 18F-NaF PET. MRI therefore 
seems to have potential to rule out acute FOP activity. Chronic FOP activity, however, was 
not to detectable by MRI. This was unexpected, as in a mouse model growth of HO was 
always associated with oedema (16). This finding emphasizes the difference between the FOP 
phenotype in humans and the R206H Acvr1 knock-in mice.
The specificity to detect HO forming FOP activity using MRI was only 29%, as five oedematous 
lesions did neither show increased uptake on 18F-NaF PET, nor did these lesions lead to HO 
progression. The implication of these oedematous lesions is still unknown. It most likely is 
a manifestation of FOP itself, as MRI studies in healthy individuals did not or only sporadically 
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showed oedematous lesions (20,21). One might hypothesize that lesions with mild oedema 
might reflect a very early stage of disease in which inflammation might still resolve 
spontaneously. In the current data set, only six months CT follow-up data was available. 
Whether these mild lesions develop into either the acute or the chronic stage even beyond 
these six months, remains unclear and will need further investigation. 
MRI was compared with 18F-NaF PET, a modality that was introduced recently as a method 
to quantify disease activity (6-8). 18F-NaF PET detects metabolic changes within tissues, as the 
18F-NaF-ion binds to newly formed hydroxyapatite(22). MRI, on the other hand, detects 
inflammation through the presence of oedema (10). In the present study, the intensity of 
oedema did not appear to correlate with the uptake of 18F-NaF PET, nor with HO formation 
or progression. One should take into account that prednisolone was used during flare-ups 
to suppress inflammation, which may have interfered with the results. 
Although 18F-NaF PET is an established technique to evaluate ossifying disease activity in 
FOP, MRI (if validated in FOP) would be especially useful in paediatric patients, as it does 
not involve exposure to radiation. In addition, MRI is more widely available than PET. Finally, 
MRI might be informative in the very early detection of a flare-up as inflammation is the 
first stage of FOP lesion formation (23), as found in one lesion in the current dataset.
The results of the present study indicate that both MRI and 18F-NaF are able to identify the 
acute stage in FOP, i.e. flare-ups, but that MRI is not suitable for identifying the chronic stage, 
i.e. progression of HO in the absence of any clinical signs. There is, however, a third stage, 
characterised by mild oedema (table 3), which requires further investigation as it is not fully 
understood. This stage might be a reversible stage that either develops into the acute or 
chronic stage (moderate to severe oedema and 18F-NaF PET positive) or resolves without 
HO growth. 
 Another finding of the present study was the long duration of oedema present at flare-up 
sites. Oedema was observed for five months after onset of a flare-up. In previously reported 
cases, MRI was performed only within 2 to 5 weeks after the onset of a flare-up (11,15). It 
therefore seems that the inflammation that coincides with a flare-up, might be present for 
a longer period. The significance and explanation of this long duration of oedema needs to 
be further investigated.
The MRI rating used in this study (mild, moderate or severe) is based on previous studies 
(17,19). The degree of muscle inflammation was based on the overall impression of the muscle 
(e.g. swelling) due to the inflammation (17). Both in the present and in previous studies the 
agreement between two readers was moderate to good (17).
The present study is limited by its retrospective design, resulting in different protocols used 
for MR imaging. The resolution of images differs only slightly between imaging protocols, 
Chapter 4
54
it is therefore likely that this has had no influence on our judgement of the oedema. In 
addition, in one patient both a field strength of 1.5 and 3 tesla were used. In STIR sequences, 
however, differences in field strength are not expected to affect the appearance of 
oedema(24). A further limitation was the availability of longitudinal 18F-NaF PET/CT and MRI 
scans of only 4 patients. This is due to the extreme rarity of the disease, poor mobility of 
patients and unpredictability of flare-ups. One could also argue whether newly formed 
cartilage could be misdiagnosed for oedema, but this is unlikely, as, compared with oedema, 
cartilage has lower signal intensity, is more compact and shows structural distortion of 
muscle morphology (25,26).
In conclusion, this study is the first to compare longitudinal imaging data between MRI and 
18F-NaF PET/CT in order to establish the diagnostic value of MRI in FOP. MRI is particularly 
helpful in identifying muscle oedema in FOP patients, indicating a concomitant inflammatory 
process. Moderate and severe oedema resulted in the formation of HO in 6 out of 7 lesions. 
However, only half of the oedematous lesions on MRI eventually developed into HO. 
Moreover, MRI could not detect chronic FOP disease. The significance of mild oedematous 
lesions on MRI that were not related to HO or 18F-NaF PET/CT needs further exploration. 
Table 3. Proposed stages of FOP activity based on MRI and 18F-NaF PET/CT findings according to Eekhoff & 
Botman
Stages MRI oedema 18F-NaF PET/CT activity FOP disease stage
0 - - No FOP activity 
1 + - Inflammatory stage
2 - + Chronic stage
3 + + Acute stage
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Fibrodysplasia ossificans progressiva (FOP) is a rare disease in which heterotopic ossification 
(HO) is formed in muscles, tendons and ligaments. Traumatic events, including surgery, are 
discouraged as this is known to trigger a flare-up with risk of subsequent HO. Anesthetic 
management for patients with FOP is challenging. Cervical spine fusion, ankylosis of the 
temporomandibular joints, thoracic insufficiency syndrome, restrictive chest wall disease, 
and sensitivity to oral trauma complicate airway management and anesthesia and pose 
life-threatening risks.
We report a patient with FOP suffering from life-threatening antibiotic resistant bacterial 
infected ulcers of the right lower leg and foot. The anesthetic, surgical and postoperative 
challenges and considerations are discussed. In addition, the literature on limb surgeries 
of FOP patients is systemically reviewed. 
The 44 year-old female patient was scheduled for a through-knee amputation. Airway and 
pulmonary evaluation elicited severe abnormalities, rendering standard general anesthesia 
a rather complication-prone approach in this patient. Thus, regional anesthesia, 
supplemented with intravenous analgosedation and N2O-inhalation were performed in this 
case. The surgery itself was securely planned to avoid any unnecessary tissue damage. 
Postoperatively the patient was closely monitored for FOP activity by ultrasound and 18F-NaF 
PET/CT-scan. One year after surgery, a non-significant amount of HO had formed at the 
operated site.
The systematic review revealed seventeen articles in which thirty-two limb surgeries in FOP 
patients were described. HO reoccurrence was described in 90% of the cases. Clinical 
improvement due to improved mobility of the operated joint was noted in 16% of the cases. 
It should be noted, though, that follow-up time was limited and no or inadequate imaging 
modalities were used to follow-up in the majority of these cases. 
To conclude, if medically urgent, limb surgery in FOP is possible even when general 
anesthesia is not preferred. The procedure should be well planned, alternative techniques 
or procedures should be tested prior to surgery and special attention should be paid to the 
correct positioning of the patient. According to the literature recurrent HO should be 





Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease with heterotopic 
ossification (HO) occurring in muscles, tendons and ligaments (1-3). HO usually leads to 
immobility of the affected joint, resulting in wheelchair-dependence at an early age (4). A 
flare-up often precedes the formation of this ectopic bone (1-4). A flare-up can occur 
spontaneously, but can also be triggered by a trauma (2,4). Because trauma causes flare-ups 
and therefore aggravates the disease, patients are instructed to be careful (e.g., do not 
engage in contact sports), to refuse intramuscular injections and to prevent any kind of 
surgery (5). In some cases, though, surgery is inevitable when a medical condition is life-
threatening. Surgical procedures can be difficult as extensive HO throughout the body has 
led to ankyloses of joints and has changed the patient’s anatomy, making proper positioning 
of the patient difficult (4). Also, the anesthetic procedures are complex. The jaw of the patient 
is often ankylosed and pulmonary function can be severely restricted. As a result, standard 
anesthesia techniques can often not be applied to FOP patients (4,6,7).
We report a patient with FOP who underwent a through-knee amputation due to a life-
threatening antibiotics resistant infection. The surgical, anesthetic and postoperative 
considerations and challenges will be discussed. In addition, a systematic review on surgical 
procedures of the limbs and the course of the postoperative disease activity in FOP patients 
undergoing limb surgery is described. 
2. Case report
The patient, a 44 year old woman at the time of surgery, is known with the classical mutation 
(p.Arg206His) of FOP. Due to widespread HO throughout the body, she has been wheelchair 
bound and ADL (activities of daily life) dependent for over 25 years. Her joints are almost 
completely ankylosed except for ankles, toes, wrists and fingers i.e. cumulative analogue 
joint involvement scale (CAJIS) score of 24 out of 30 (8). A recent pulmonary function tests 
showed a severely reduced Forced Expiratory volume in one second (FEV1) (0.6L, 25% of 
predicted) and forced vital capacity (FVC) (0.6L, 22% of predicted) with a normal Tiffeneau 
index (94%). This suggests a severely restrictive pulmonary function, compatible with marked 
chest wall rigidity (9). In 2016 the patient recovered without sequelae from a cerebrovascular 
accident (CVA), for which she is on chronic anticoagulation therapy (thrombocyte aggregation 
inhibitor). In addition, her fifth digit of the right foot was amputated in 2001 because of an 
incurable osteomyelitis. This procedure has previously been described (10). 
The patient has been treated in our center since 2016 for recurrent skin infections of the 
right lower leg and foot as a result of progressive chronic ulcers. Initially, the ulcer at the 
foot led to recurrent cellulitis of the right lower leg, with good response to antibiotic 
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treatment. Wound care led to improvement of the ulcer, but oedema complicated healing. 
Bandages, intensive wound care and targeted systemic and topical antimicrobial treatment 
for any inter current infection, resulted only in temporary improvement of wound healing. 
A neuropathic pain syndrome, clinically confirmed by the neurologist, was thought to be 
the cause of the allodynia in the right lower leg. In addition, repeated pressure on the skin 
while sitting in her wheelchair contributed to formation these ulcers. Custom-made 
orthopedic shoes and other biomechanical offloading devices were therefore used, and led 
initially to an improvement of the ulcers. Unfortunately, after years of treatment the ulcers 
and infections progressed, with antibiotic resistant microorganisms (pseudomonas 
aeruginosa) (Figure 1). We expected her to develop a life-threatening sepsis in the near 
future. In a multidisciplinary FOP team, consisting of an endocrinologist, infectious disease 
specialist, pulmonologist, surgeon, anesthesiologists and rehabilitation specialist, the case 
was thoroughly discussed. The team concluded that amputation of the infected part of the 
lower leg was the only life-saving option. The patient was well informed about the risks of 
the anesthesia, surgery and the risk of FOP activity after surgery and consented for a surgical 
procedure. 
2.1 Anesthetic management 
Anesthesiologists of our FOP expertise center in Amsterdam managed the anesthetic care. 
General anesthesia was intentionally avoided as airway management appeared rather 
challenging in this patient with severely impaired mouth opening (<2mm). Moreover, 
Figure 1. FOP patient with multiple incurable ulcers at the right lower extremity. Left plane: ulcer located 
at the right calcaneus. Despite Intensive wound care, custom-made orthopedic shoes and targeted systemic 
and topical antimicrobial treatment, surgical intervention was unavoidable. Due to an ulcer on the calf (right 
plane) and proximal from the knee, a through-knee amputation was thought to be most favorable for 




mechanical ventilation was expected to temporarily cause a decline in pulmonary function, 
potentially leading to a ventilation-perfusion mismatch or barotrauma, and rendering 
weaning from mechanical ventilation impossible. Regional anesthesia was therefore selected 
as the preferred technique. Two peripheral nerve block catheters were placed at the femoral 
and sciatic nerve on the pre-operative day (Figure 2A). Damage to surrounding tissues was 
not completely avoidable, but kept to a minimum by using ultrasound guidance. The femoral 
nerve was easily identified in the femoral triangle. The identification of the sciatic nerve with 
ultrasound, however, was challenging because of an altered anatomy caused by HO (e.g., 
altered landmarks and aberrant course of the nerve). Eventually the sciatic nerve was 
identified and approached at the subgluteal level. To prevent inflammation at those sites, 
40mg methylprednisolone was administered over the two nerve block catheters. Pre-
operatively, 12ml ropivacaine 0.375% was injected in the catheters. The ropivacaine spread 
around the nerves as confirmed by sonography. Nerve block effectiveness was confirmed 
using cold discrimination tests prior to commencement of surgery. Surgery was initiated 
and anesthesia was judged adequate for the initial part of the procedure. The patient 
remained conscious and responsive throughout the procedure, but started to report some 
discomfort once surgery reached deeper tissue planes. The regional anesthesia was 
therefore supplemented by intravenous bolus titration of midazolam and s-ketamine, and 
inhalation of a mix of 50% N2O and 50% O2 via face mask. Herein, midazolam served as 
light anxiolytic and amnestic sedative, and to prevent psychomimetic side effects of 
s-ketamine. S-ketamine served as systemic analgesic without cardiovascular and respiratory 
depression. The N2O-inhalation induced additional analgesia, supplementing the analgesic 
effects of the regional anesthesia. Together, this ensured adequate analgesia and patient 
comfort for the remainder of the surgery, with a spontaneously breathing, responsive 
patient.
Postoperatively, the patient did not recall having experienced any pain during the procedure. 
The nerve catheters were used postoperatively to administer continuous bupivacaine 0,125% 
for pain control, enabling to avoid the use of systemic opioids. The catheters were removed 
eight days postoperatively when oral medication was sufficient to control pain. 
2.2 Surgical management
Due to therapy-resistant infected ulcers 10cm below the knee and more distally, it was 
decided to perform an amputation through the knee after an extensive discussion with our 
team and the patient. Thirty minutes prior to surgery, 30mg of prednisolone was 
administered intravenously to prevent flare-ups. The surgery was performed by a surgeon 
affiliated to the FOP Expert Center of Amsterdam UMC.
The positioning of the patient was challenging, due to complete immobility of the major 
joints (Figure 2B). Time was taken to carefully position the patient and soft pads were used 
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to minimize pressure on the soft tissues. Once positioned, the patient was put in adjusted 
supine position and the knee joint was marked. A tourniquet was not used to avoid tissue 
compression that may induce a flare-up. As post-operative soft tissue healing complications 
were expected, the skin flap and gastrocnemius muscle transposition were designed to 
opposite each other in order to minimize the chance of deep infection and fistula formation. 
While most ligaments and the capsule of the knee joint were ossified, no abnormalities were 
observed in the knee joint itself (Figure 2C). As the patella was fused with the distal femur, 
it was left in situ to minimize tissue damage. Furthermore, the popliteal artery and nerve 
were difficult to identify initially, as the patient’s leg was in a fixed position. This posed a 
potential risk in case of laceration of the vessel, but could be avoided by diligence.
Figure 2. Anesthetic and surgical management of a through-knee amputation in an FOP patient
A: Two peripheral nerve block catheters were placed under ultrasound guidance at the femoral and sciatic 
nerve. Pre-operatively nerve block effectiveness was tested and confirmed. During surgery, the regional 
anesthesia was complemented with the administration of midazolam, s-ketamine and N2O-inhalation. B: The 
patient was carefully positioned on the theater table to prevent any tissue damage that might cause FOP 
disease activity. C: Surgical procedure was performed carefully to minimize tissue damage that might cause 
a flare-up. D. the skin flap and gastrocnemius muscle transposition were designed to opposite each other. 




The gastrocnemius muscles were transposed forward and fixed near the patella region to 
cover the bone, to provide a vascularized bed and to protect underlying tissues in case of 
a future prosthesis (Figure 2D). The anterior skin of the proximal lower leg was fixed to the 
posterior skin at the level of the knee. 
Postoperatively, extra padding was applied between the lower extremities, to avoid pressure 
from the left knee on the wound of the stump. The patient developed partial skin necrosis 
laterally of the stump (Figure 2D), but healed with supportive care.
2.3 Postoperative management
The patient’s disease activity was closely monitored with ultrasound imaging and 18F-NaF 
PET/CT (sodium fluoride positron emission tomography and computed tomography). 
Ultrasound imaging was obtained daily to evaluate oedema at the surgical site and at the 
site of the anesthetic catheters. From day one until day fourteen, mild oedema was seen 
laterally from the stump by ultrasound. This oedema, however, did not progress over time. 
It was interpreted as a normal postoperative tissue reaction. To evaluate osteoblastic activity, 
an 18F-NaF PET/CT-scan was obtained fourteen days after surgery, showing only a mild 
increased 18F-NaF-uptake (Standardized uptake value (SUVmax): 6.4) at the base of the distal 
femur. Because the postoperative 18F-NaF uptake was only slightly elevated (11), it was decided 
not to administer extra prednisolone. A follow-up 18F-NaF PET/CT-scan was obtained eight 
weeks after surgery, revealing minimal HO formation (4 cc) at the base of the femur (Figure 
3). Another follow-up scan obtained twelve months after surgery, revealed no further 
progression of HO evaluated by CT. Interestingly, the patient’s disease activity as evaluated 
by 18F-NaF-activity on PET, now showed an increased 18F-NaF-uptake at multiple sites of HO 
throughout the body, whereas in the previous four years there has not been any 18F-NaF 
activity nor a volumetric increase of HO as evaluated by CT. The quiescence of disease was 
in a period of progressive infectious ulcers and under continuous antibiotic therapy before 
surgery.
After fourteen days, the patient was transferred to a rehabilitation center. Since the patient 
was unable to see the stump and still feels the presence of her amputated lower leg, 
rehabilitation was needed to make her aware of the new situation and to find a new balance 
during transfers. After four months, the patient returned home. At the most recent follow-
up, fourteen months after the surgery, the patient was doing well. Now, the patient is under 
the care of the department of rehabilitation medicine at Amsterdam UMC exploring the 




Literature was systemically reviewed to identify cases in which FOP patients underwent 
surgery of a limb and the effect of the procedure on the disease activity. The literature 
search was performed based on the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA)-statement (www.prisma-statement.org). 
To identify all relevant publications, we conducted systematic searches in the bibliographic 
databases PubMed and Embase from inception to May 2, 2019, in collaboration with a 
medical information specialist. The following terms were used (including synonyms and 
closely related words) as index terms or free-text words: “Myositis ossificans”, “Fibrodysplasia 
ossificans”, “Surgery”, “Anesthesia”. The references of the identified articles were searched 
for relevant publications. Duplicate articles were excluded. Only English articles were 
accepted. The full search strategies for all databases can be found in the Supplementary 
material.
Two reviewers (EB and ST) independently screened all potentially relevant titles and abstracts 
for eligibility. If necessary, the full text article was checked for the eligibility criteria. 
Differences in judgement were resolved through consensus. Studies were included when 
a surgical procedure of the limb and its outcome (either HO-formation or clinical outcome) 
were described. Patients of all ages were included, as well as all types of surgeries. 
The literature search generated a total of 1774 references: 692 in PubMed and 1082 in 
Embase. After removing duplicates of references that were selected from more than one 
database, 1223 references remained. The flow chart of the search and selection process is 
Figure 3. Axial Low dose CT-images at the level of the distal femur of a patient prior to and after a through-
knee amputation of the right leg. 
A: Eight months prior to the surgery. B: Twelve months after the surgical procedure. Minor HO formed (4cc) 
on the right side posterior to the lateral femoral condyle (red arrow). Abbreviations: FOP = fibrodysplasia 




presented in figure 4. Seventeen articles described cases in which FOP patients underwent 
surgery for the upper and/or the lower limbs. In these seventeen articles, thirty two 
procedures were described in twenty patients. Ten procedures involved the upper limbs(12-19), 
twenty-two the lower limbs (12,13,19-28). 
3.1 Procedures on the upper extremities
All ten surgeries performed on the upper limbs were done to remove either an undiagnosed 
swelling or mature HO. The reoccurrence of HO was described for eight of the ten procedures 
(12-15,18,26) and the clinical outcome for nine cases (12,14,15,18,19,26). Reoccurrence of HO was 
observed in all eight procedures, however, in four of the nine procedures for which the 
clinical outcome was described, a clinical improvement was noted (12,15,19). Clinical 
improvement in one patient was due to a better position of the joint(15), whereas three other 
Figure 4. Flowchart of the study selection process
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cases describe an improved movement in the joint after surgery(12,19). For these cases, though, 
the follow-up period was five to six months. The time for HO to redevelop after surgery was 
only described in only one case, i.e. 3 months (15). In the majority of the cases, the method 
to detect reoccurrence of HO and its extensiveness was not described. In all reports, neither 
the anesthetic management nor the selected operative method were discussed.
3.2 Procedures on the lower extremities 
Of the twenty-two described lower limb surgeries, performed in sixteen patients, twenty 
procedures were performed to remove HO and restore joint mobility (12,13,19-21,23,24,26,27). In one 
case, however, surgery was needed for fracture management (25), and in another case the 
operation was to close a chronic ulcer with skin grafts (28). In all but three cases in which HO 
reoccurrence was described (19/22), the removal of HO was complicated by reoccurrence 
of HO at the operated site(12,13,19,20,23-26,28). Two of these three cases without any HO recurrence 
involved more than just the skin, however, adequate follow-up data on these cases are 
lacking(19). The time before HO was noticed ranged from four weeks to thirty-six months 
(13,19,20,23,24,26). Despite reoccurrence, however, five of the sixteen cases in which clinical 
outcome was described, a clinical improvement after surgery was found (13,19,21,26,27). Two 
surgical procedures were done because of compression of HO on surrounding tissues, and 
resulted in less pain(21,27). In two cases mobility was not restored, but a better position of the 
joint was achieved, increasing functionality(20,26). In only one patient there was an actual 
improvement of mobility of the operated joint(13). The anesthetic management was 
mentioned, but not discussed in detail, in three case reports. Surgery to unlock the hip was 
performed under general anesthesia, whereas surgery on the knee joint was done under 
a subarachnoid block. 


































































































































1 14 Y Shoulder Unlock joint Y U U U -




RT: 7Gy in 1 fraction
Colmenares-
Bonilla et al. 
(2018)
2 11 Y Knee Unlock joint Y1 1 60 N Corticosteroids 30mg/




3 1 N Shoulder Remove swelling Y - U N -
4 6 U Shoulder Unlock joint Y U U N -
Corfield  
et al. (2000)







































































































































6 17 Y Hip HO induced 
claudication





7 20 Y Hips Unlock joint Y1 2 24 N EHDP 10mg/kg/day
Jayasundara  
et al. (2012)




Hip Unlock joint Y2 U U N Bisphosphonates, 
indomethacin
52 Hip HO induced 
pressure 
necrosis




9 13 N Hip Unlock joint Y 1.5 12 N -
14 N Hip Unlock joint Y 3 12 N -
15 N Hip Unlock joint Y U 12 N -
Smith  
et al. (1976)
10 34 U Calf Unlock joint N1 - U U EHDP 20mg/kg/day
Elbow Unlock joint U - U Y: improved 
mobility
EHDP 20mg/kg/day
11 16 U Foot Unlock joint Y 3 3 U
17 Foot Unlock joint Y U U U
18 Hip Unlock joint Y U U U
23 Foot Unlock joint Y1 36 36 U EHDP 20mg/kg/day
U Hip Unlock joint Y1 7 7 N EHDP 20mg/kg/day
12 17 U Hamstring Unlock joint Y U U U Prednisone 7.5mg/day
18 Biceps Unlock joint U - U Y: improved 
mobility
EHDP 20mg/kg/day
Hip Unlock joint N1 - 24 Y: improved 
mobility
EHDP 20mg/kg/day
13 21 U Hip1 Unlock joint Y 2 5 N EHDP 20mg/kg/day
Kocyigit  
et al. (2001)
14 15 N Elbow Unlock joint Y U U N -
Matsuda  
et al. (2014)
15 35 Y Malleolus Incurable ulcer N - 8 N -
Nerubay  
et al. (1987)
16 7 Y Femur Fracture Y U 12 N -
Obamuyide  
et al. (2015)
17 11 N Axilla Unlock joint Y U U N -
Tiwari  
et al. (2018)
18 2 N Arm Removal swelling Y U U N -
Trigui  
et al. (2011)






20 23 Y Hip HO induced pain U - U Y: less 
discomfort
-
HO reoccurrence is stated as YES when the article has specifically mentioned the reoccurrence of HO, YES1 when confirmed by 
X-rays and YES2 when confirmed by CT. 
FOP diagnosis is states as UNKNOWN when the confirmation of the diagnosis was not specifically mentioned in the article. 
Abbreviations: FOP = fibrodysplasia ossificans progressiva, Y/N/U = yes/no/unknown; HO = heterotopic ossification; RT = 




3.3 Perioperative medication to prevent HO
Medication was used prior, during or after the procedure in 15 of the 32 surgeries(12,13,19,20,23,26). 
In twelve of these cases bisphosphonates were used in attempt to halt (re)
mineralization(12,19,20,23,26). Bisphosphonates were given as monotherapy (n=8), or combined 
with non-steroidal anti-inflammatory drugs (n=2) or corticosteroids (n=2). The other 
treatments given were either NSAIDs combined with one fraction of radiotherapy (n=1), 
subsequent fractions of radiotherapy (n=1) or corticosteroids (n=1)(12,13,19). For eleven of those 
fifteen procedures the effect of the procedure on HO reoccurrence was described: ten were 
followed by HO reoccurrence. The one case in which there was no reoccurrence, the duration 
of follow-up is unknown(19). Outcomes in the group without treatment (n=17) were described 
for fifteen procedures: fourteen were followed by HO. The one case without reoccurrence 
was a superficial surgical procedure involving a skin graft for an ulcer on the malleolus(28). 
4. Discussion
Although any kind of surgery is highly discouraged in FOP patients due to an increased risk 
of flare-ups and progression of the disease, this case demonstrates that in a life-threatening 
situation - an operative procedure can be considered and managed successfully even in 
severely affected patients. It requires the assembly of a multidisciplinary FOP-dedicated 
team with knowledge of the disease and preparations made in anticipation of complications 
that may occur. In the current case, the timely and detailed preparation on the 
multidisciplinary team and the innovative techniques employed throughout the perioperative 
period assured the benign outcome of the surgical procedure. 
Because there is no effective treatment available to stop the formation and progression of 
HO, surgical procedures are highly discouraged as standard care of FOP(5,29). Even small 
traumata – e.g. biopsies – can cause sufficient damage to the muscle and trigger a flare-up 
with subsequent HO formation (30). In the described case, surgery was the only life-saving 
option: it was judged that the patient was unlikely to survive the rapidly increasing, 
progressive infections of her leg due to antibiotic resistant organisms after many years of 
treatment. Surprisingly, a negligible amount of HO formed after the through-knee 
amputation, possibly due to a period of silent disease activity before and at the time of the 
operation. The reason for the quiescent disease in this patient is not known. One hypothesis 
is that, as it is known that the immune system plays a role in the pathogenesis of HO(31), the 
chronic inflammation and antibiotic use could have suppressed disease activity. Interestingly, 
twelve months after the surgical procedure disease activity was noted at various sites with 
HO. This could be the result of a normalized level of inflammation, or a systemic, late effect 
of the surgical procedure itself. 
Based on case reports in literature describing limb surgeries, where postoperatively HO 




relevant HO would form. It should be noted, that over 90% of the published limb surgeries 
were performed to remove HO. Only in two patients (7%) HO did not reoccur after the 
removal of HO. Both patients received bisphosphonate treatment(19). Due to the absence 
of the effect of bisphosphonate treatment in nine others, it is more likely that the good 
result in those two can be attributed either to an incomplete follow-up time or due to limited 
imaging modalities as both cases are reported in 1976 (19). 
Removal of HO might be complex when it has formed within a muscle or when it has fused 
with normal skeletal bone. Removal of HO can therefore be considered as a high impact 
procedure which triggers HO formation. In our case a through-knee amputation was 
performed which is a procedure with relatively limited trauma to muscles because the 
procedure does not affect normal skeletal bone and it mainly involves the origin and 
insertion of muscles and tendons. In addition, when possible, ankylosed bone parts were 
left in situ to minimize tissue damage.
To limit the extent of HO formation after surgery, it has been suggested to administer 
corticosteroids as a prophylaxis for four consecutive days after surgery (5). Objective data 
on the effectiveness of glucocorticoids in flare-ups are lacking. But based on empirical data, 
it is believed that it reduces oedema and may cause symptom relief(4). Glucocorticoids are 
currently the only treatment available for FOP. Corticosteroids, however, also interfere with 
wound healing. Therefore, in the current case, they were only administered pre-operatively. 
Hopefully, an effective treatment will be available to halt the formation of HO in the near 
future. To date, four potential drugs are tested in a clinical trial: Palovarotene, Garatosmab, 
Rapamycin and Saracatinib (32-35). Once found effective in preventing HO formation, surgical 
treatment might be an option to unlock joints or to safely operate an FOP patient for any 
other condition under an umbrella of one (or a combination) of these drugs.
Besides the impact of the surgical procedure and the attempt to suppress FOP activity with 
glucocorticoids, the anesthetic management is another major concern and challenge in FOP 
patients. Regional anesthesia techniques (peripheral nerve blocks) involve punctures causing 
tissue trauma with increased risk of flare-ups, and these are therefore considered 
contraindicated. Likewise, neuraxial (spinal or epidural) anesthesia is not recommended for 
the following reasons. First of all, the spine is often involved in the disease and thus 
inapproachable for puncture. Secondly, the puncture itself might trigger HO formation, 
which could compress the spinal cord(5). Therefore, general anesthesia is generally 
recommended for FOP patients. General anesthesia requires airway management and 
frequently mechanical ventilation, both of which can be extremely challenging in FOP 
patients(36,37). FOP patients often have jaw ankyloses, making conventional direct laryngoscopy 
or even video-laryngoscopy impossible for tracheal intubation. Moreover, even in the 
absence of a temporomandibular joint (TMJ) ankylosis, direct laryngoscopy is discouraged 
because hyperextension of the neck is limited - if not impossible - due to fused cervical 
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vertebrae and in addition, overstretching of the TMJ joint or vertebral facet joints during 
tracheal intubation might induce a temporomandibular joint flare-up(5). Therefore, fiberoptic 
naso-tracheal intubation is preferred in all FOP scheduled for general anesthesia(5). This 
would have been possible in the current case, however, the risk of general anesthesia was 
deemed unacceptably high. The patient suffered from a severely restricted pulmonary 
function due to a completely immobile thoracic cage(7,9). It was anticipated that high 
inspiratory airway pressures would be needed during mechanical ventilation to maintain 
adequate gas exchange. This can lead to over-distention of alveoli causing pulmonary 
barotrauma(38). Other challenges that were anticipated were a ventilation-perfusion mismatch 
and difficulties in weaning form mechanical ventilation. In addition, FOP patients are known 
to have impaired thoracic flexibility and weakened respiratory muscles predisposing to 
ineffective coughing, with an increased risk of mucus retention and infection(5). Therefore, 
a regional anesthesia approach was chosen, with ultrasound guidance to identify structures 
and to limit tissue trauma. Glucocorticoids were locally injected via the placed nerve block 
catheters in an attempt to prevent a flare-up. Since regional anesthesia alone was insufficient 
to ensure complete analgesia and patient’s comfort, systemic drugs were added. As these 
drugs might induce apnea, it is important to monitor the patient closely and keep high-flow 
nasal oxygen standby in case support of oxygenation is needed (39,40).
To conclude, based on the literature it was almost certain that HO would form as a response 
to a surgical procedure of a limb. In the current case, HO was indeed formed, but even 
twelve months after surgery the volume of the formed HO minimal. It is hypothesized that 
the patient’s silent disease activity and the continuous antibiotic treatments might have 
influenced this. If surgery needs to be performed, it is important that it is performed by a 
multidisciplinary team with knowledge about FOP and after carefully weighing the surgical 
benefits against the challenges and risks of both the anesthetic and surgical procedures for 
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Supplementary table 1. Terms used in Pubmed to identify studies describing surgery in patients with 
fibrodysplasia ossificans progressiva 
Search Pubmed Query – May 2, 2019 Items 
found
#3 #1 AND #2 692
#2 “Surgical Procedures, Operative”[Mesh] OR “Anesthesia”[Mesh] OR surger*[tiab] 
OR surgical*[tiab] OR operation*[tiab] OR operative*[tiab] OR perioperati*[tiab] 
OR anesthe*[tiab] OR anaesthe*[tiab] OR incis*[tiab] OR extract*[tiab] OR 
excis*[tiab]
5,076,112
#1 “Myositis Ossificans”[Mesh] OR myositis ossificans[tiab] OR ossifying 
myositis[tiab] OR fibrodysplasia ossificans[tiab] OR ossifying fibrodysplasia[tiab] 
OR FOP[tiab] OR Munchmeyer*[tiab]
2,937
Supplementary table 2. Terms used in Embase to identify studies describing surgery in patients with 
fibrodysplasia ossificans progressiva
Search Embase Query – May 2, 2019 Items 
found
#3 #1 AND #2 1,082
#2 ‘surgery’/exp OR ‘anesthesia’/exp OR surger*:ab,ti,kw OR surgical*:ab,ti,kw OR 
operation*:ab,ti,kw OR operative*:ab,ti,kw OR perioperati*:ab,ti,kw OR 
anesthe*:ab,ti,kw OR anaesthe*:ab,ti,kw OR incis*:ab,ti,kw OR extract*:ab,ti,kw OR 
excis*:ab,ti,kw
6,866,560
#1 ‘ossifying myositis’/exp OR ‘myositis ossificans traumatica’/exp OR ‘fibrodysplasia 
ossificans progressiva’/exp OR ‘myositis ossificans’:ab,ti,kw OR ‘ossifying 
myositis’:ab,ti,kw OR ‘fibrodysplasia ossificans’:ab,ti,kw OR ‘ossifying 
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Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant disease, characterized 
by the formation of heterotopic ossification (HO) in muscles, ligaments and tendons. Flare-
ups, an inflammatory process that often precedes the formation of HO, can occur 
spontaneously, but trauma is also a common trigger. It is not known whether radiotherapy, 
especially in higher doses, might cause sufficient trauma or inflammation to trigger a flare-
up and subsequent HO in FOP patients. 
We report the case of a patient undergoing radiotherapy for the treatment of a 1 centimetre 
wide basal cell carcinoma (BCC) of the lower lip. In addition, we present a systematic review 
of the available literature. Our patient received 54 Gy in 18 fractions with orthovoltage 
therapy, resulting in a clinical complete response of the tumour. Six months after treatment, 
there were no signs of HO either clinically or on 18F-NaF PET/CT. 
The systematic review identified eleven publications describing either radiation treatment 
in FOP or radiation therapy as a cause of HO in non-FOP patients. Six case reports described 
the use of radiation in FOP patients for various reasons, including one with a high dose 
treatment of a lip BCC using superficial X-ray therapy. The remaining five studies described 
the use of low dose radiotherapy to prevent or treat either a FOP flare-up or HO formation. 
None of these cases showed worsening of disease that could be attributed to the use of 
radiation therapy. Radiation induced HO in non-FOP patients was rare and occurred in five 
studies. The largest of these studies suggested that HO was induced after treatment with 
high doses, resulting in more widespread evidence of tissue damage, potentially being the 
end result of this damage.
In conclusion, available reports suggest no contraindication to radiotherapy in FOP patients, 
although the number of cases was small, systematic toxicity reports often were not available 
and none of the reports described high dose, high energy radiation treatment at locations 





Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant disorder, which is 
characterized by heterotopic ossification (HO) in muscle, ligaments and tendons (1,2). First 
ossifications usually develop at the age of six, often affecting the upper back or neck region. 
With aging, the formation of HO extends to appendicular regions (3). Often, HO formation 
is preceded by a flare-up, an inflammatory process of uncertain origin (2,3). Flare-ups can be 
provoked by (minor) trauma and infections, but can also occur spontaneously (3). Whether 
radiotherapy can cause sufficient trauma to trigger a flare-up, leading to HO, is unclear. 
Previously, we have demonstrated that 18F-NaF PET can be used to detect activity of disease 
just prior to the formation or progression of HO (4-6). Intravenously administered labelled 
sodium fluoride (18F-NaF) binds to newly formed hydroxyapatite and, therefore, can be used 
to detect osteoblastic activity (7). We previously reported that increased 18F-NaF uptake was 
observed within one month of surgery as the first sign of HO recurrence in a FOP patient, 
confirmed six months later with CT (6). If radiotherapy does indeed lead to HO formation, it 
should be detectable by either increased 18F-NaF uptake on PET, or the presence of HO at 
the irradiated site on a follow-up CT. 
In this paper we describe a 67-year old male patient with FOP, who underwent radiation 
treatment for a basal cell carcinoma (BCC) of the lower left lip. To place results into context, 
we then performed a systematic review of ther literature to address whether radiotherapy 
is safe in FOP patients. 
2. Case report
A 67 year old male patient with FOP presented with a 1 cm wide, progressive lesion of the 
lower left lip. The patient has the classic variant (R206H) of FOP. The cumulative analogue 
joint involvement scale (CAJIS) score was 25 (8). The patient had not had a flare-up for at least 
5 years. However, disease activity was observed at multiple sites on 18F-NaF PET/CT 
performed during annual follow-ups. 
A skin biopsy, performed with caution to minimize damage to surrounding tissues, diagnosed 
an infiltrative basal cell carcinoma (BCC). It extended up to the deep biopsy margin (2 mm). 
Since surgery is a known as a trigger for a flare-up, radiation treatment was preferred over 
surgical excision. Because the patient is wheelchair bound due to FOP, orthovoltage therapy 
was considered as the most practical method, as he could remain in his wheelchair during 
treatment. The patient underwent 18 sessions (fractions) of radiotherapy over a period of 
approximately 4 weeks, with each fraction delivering a dose of 3 Gy for a total dose of 54 
Gy. The BCC showed complete clinical remission after treatment. However, soon after 
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treatment, the patient reported increased difficulty in eating because of decreased mobility 
of the lower lip. In combination with pre-existing jaw ankyloses, the loss of lip mobility 
increased the difficulty of eating and drinking. To assess whether these problems were 
caused by formation of HO in the irradiated area, 18F-NaF PET/CT (Gemini TF-64; Philips 
Medical Systems, Best, The Netherlands) was performed. This scan, performed 6 months 
after completion of radiation therapy did not show any evidence of HO formation, i.e. no 
increased tracer uptake in the irradiated area, nor any CT evidence of HO in the treated 
region. In addition, the radiation therapy did not lead to a significant increase in overall 
activity of disease throughout the body. Almost 2 years after the irradiation, there was still 
no sign of HO formation at the irradiated site, confirmed by physical examination. 
3. Systematic Review
This systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) statement (www.prisma-statement.org). 
A comprehensive search was performed in the bibliographic databases PubMed and 
Embase.com from inception to December 6th 2018, in collaboration with a medical librarian 
(LS). Search terms included controlled terms (MesH in PubMed and Emtree in Embase) as 
well as free text terms. The following terms were used (including synonyms and closely 
related words) as index terms or free text words: ‘fibrodysplasia ossificans’, ‘radiotherapy’, 
‘heterotopic ossification’ and ‘myositis ossificans’. The search was performed without date 
or language restrictions. Duplicate articles were excluded. The full search strategies for all 
databases can be found in the Supplementary Materials.
731 articles were identified using this search strategy. Articles describing radiotherapy in 
FOP patients or radiation therapy as a (probable) cause of HO were eligible for inclusion 
(figure 1). The articles were systematically assessed by two independent reviewers (EB and 
JCN). Discrepancies were resolved by consensus. After screening titles, abstract and articles, 
11 publications were selected for this systematic review. Of these 11 articles, six articles 
addressed radiotherapy in FOP, and five the relationship between irradiation and the 
formation of HO. 
3.1 Radiotherapy in fibrodysplasia ossificans progressiva
Not including our own case, radiotherapy in FOP has been described in six other case reports 
(table 1). One case reported the radical (high dose) treatment of a lip BCC using superficial 
(90 Kv) X-ray therapy (9). The remaining five cases described the use of low dose radiotherapy 
to prevent or treat FOP flare-ups or HO formation (10-14). In 4/5 of these cases, a beneficial 
effect on flare-up symptoms or HO formation was reported (10-13). In 2/5 cases, one or two 
additional treatment modalities were also reported: a nonsteroidal anti-inflammatory drug 




clinical deterioration or excessive toxicity as a result of radiotherapy (containing) treatment. 
All, but one, reported a relatively low dose of radiation (10,12-14), consistent with the literature 
on HO prevention in non-FOP patients (15). Interestingly, Soldic et al. described clinical and 
radiological benefits after very low doses of fractionated radiotherapy (as low as 2 Gy in 2 
fractions) (12). In the remaining case, which was very similar to ours, a patient received 35 Gy 
in 5 fractions on consecutive days for the treatment of a right upper lip BCC. There was a 



































complete response with no evidence of HO at the irradiated site (9). Whether this was 
confirmed radiographically is not known. In addition, the time interval between radiation 
therapy and follow-up was not reported. In summary, based on a limited sample of 7 
patients with FOP (including ours) a range of radiotherapy doses appear to have been well 
tolerated, with no reports of excessive or unexpected HO formation and no reports to 
suggest that the intended outcomes (primarily prevention, treatment of HO and treatment 
of BCC) were any worse than expected. However, there was no systematic toxicity reporting 
and none of the reports described high dose, high-energy, treatment at specific sites, 











































































































































































































































































































































































































































































































































































































































































































































3.2 Development of heterotopic ossification in non-FOP patients treated with 
radiotherapy
Five studies were found suggesting that radiation received by non-FOP patients eventually 
led to HO at the irradiated site (table 2) (16-20). The interval between actual treatment and 
formation of HO varied between 1 and 33 years. The largest patient series was from Carl et 
al. who reported on 15 cases with a range of primary tumours (breast, anal, endometrial, 
sarcoma, seminoma, bladder and cervical) (17). Radiation types varied, and include cobalt, 
neutrons and brachytherapy. Biologically effective doses (for late normal tissue damage, 
with α/β=3) ranged from 67 to 214 Gy. However, potential overlap between fields means 
that local doses may have been higher. HO developed 2-31 years after radiotherapy. 
Importantly, all patients first developed other signs of tissue damage ranging from 
plexopathy to ulceration and necrosis as a result of radiation therapy, leading the authors 
to propose that HO in these patients was an end stage response to the tissue damage caused 
by radiotherapy. In the other four case reports neither dose nor tissue damage as a result 
of treatment were specified (16,18-20). In 3 of these cases no other trigger than radiotherapy 
for HO was present (18-20). In the remaining case, the authors stated that HO in the ankylosed 
mandible might have been caused by a combination of factors, including chemotherapy, 
radiation, prolonged intubation, immobilization and critical illness neuromyopathy (16). 







Reason RT Dosage Time interval RT 
and HO (years)
1 Carl et al. 
(2002)
Case series 15 Various 
carcinomas
BED 67-214Gya 19 (range 2-31)
2 Kruse et al. 
(2009)
Case report 1 Nasopharyngeal 
carcinoma
Unknown 3b
3 Park et al. 
(2014)
Case report 1 Tonsil cancer Unknown 14
4 Portha et al. 
(1982)




5 Harmon et al. 
(1994)
Case report 1 Testicular tumor unknown 33
a Various kinds of radiotherapy given, potential for overlap could lead to underestimate of radiation dose
b Additional factors: chemotherapy, intubation on intensive care, immobilization, critical illness neuromyopathy
Abbreviations: RT = radiotherapy, HO = heterotopic ossification, BED = biological effective dose (with α/β=3 for 





To the best of our knowledge, this is the first systematic review of literature relating to the 
use of radiotherapy in patients with FOP. Including our own case, we found only seven cases 
in the literature. The available reports suggest that radiotherapy in FOP patients does not 
lead to the formation of HO at the irradiated site. In addition, there were no reports of 
excessive or unexpected toxicity and no indication that the intended treatment outcome 
was poorer than expected. Some caution is required, however, as the number of cases is 
very small, there was no uniform systematic toxicity reporting or post-radiotherapy 
assessment, there is limited long-term data and the effect of high dose, high energy radiation 
to, for example, muscle and joint regions was not described.
One discussion point that can be extracted from these reports is the timing of radiotherapy. 
Pignolo et al. described that most flare-ups resolved spontaneously within eight weeks, 
except those of the hip and back, and of the latter, 75% resolve within twelve weeks (3). One 
patient was irradiated for a flare-up at the iliopsoas muscle. Radiotherapy was combined 
with physiotherapy, indomethacin and disodium etidronate (13). Disodium etidronate, a 
bisphosphonate, has been used in the past to prevent formation of HO in FOP (21-23), but 
because of its varying success and side effects, nowadays its use is limited (24). The flare-up 
was present for 5 weeks prior to treatment. Two months after treatment, it was reported 
that oedema was significantly diminished and pain was relieved (13). Whether this was due 
to the multi-modality treatment or whether the lesion would have spontaneously resolved, 
is not known with certainty. However, in this case, the patient already had evidence of 
femoral neurapraxia and neurological deficits at presentation due to the mass. In such a 
situation, urgent initiation of treatment to avoid permanent nerve damage is important. 
For milder, non-threatening, flare-ups a period of observation, to see whether spontaneous 
regression occurs, would be appropriate. Although apparently effective in the short term, 
combination treatment did not prevent HO formation, as follow-up CT revealed the 
presence of calcification at the affected site (13). Unfortunately, the longer term outcome is 
not known. Soldic et al. also reported benefit of radiotherapy in their patient who underwent 
multiple irradiations at different locations over a prolonged period (12). They used 
calcification detected on radiographs or CT as a marker of disease. Interestingly, even 
though low doses of radiation, they reported non-progression of calcification for periods 
of up to 10 years, and they did not report having to treat previously treated areas again. 
In the future, it would be interesting to assess disease activity before and after treatment 




The choice between radiotherapy and other treatments, need consideration. Treatment of 
a tumour or prevention/treatment of HO formation both seem reasonable indications based 
on the literature. The choice between radiotherapy and other modalities will depend on 
various factors: 
1. The risk of secondary tumour induction by radiation, and the effect of radiation 
on bone. 
A single radiation fraction of e.g. 7 Gy, as used in myositis ossificans traumatica (MOT) 
to prevent HO, has only rarely led to a malignancy at the irradiated site (25). Pellegrini 
et al. hypothesized that this low incidence is due to the already advanced age of most 
patients developing MOT and the latency period for the malignancy to develop (26). 
Younger patients have a higher risk of developing a secondary malignancy as a 
consequence of radiation treatment (27). Even though life expectancy of FOP patients is 
limited [29] and therefore the lifetime chance to develop a secondary malignancy due 
to radiotherapy is also limited, the treatment of a secondary malignancy (e.g. by surgery) 
is catastrophic for FOP patients. 
Radiation can also have negative effects on bone metabolism, both locally and 
systemically (28). In addition, FOP patients often underwent multiple glucocorticoid 
treatments (3), which can also lead to bone toxicity, e.g. reduction in bone mineral density 
of skeletal bone. Strategies to maximize bone health and mitigate bone toxicity from 
FOP treatments are required. 
2. The potential of either a flare-up or HO formation by alternative therapy (e.g. 
surgery). 
Although Benetos et al. reported good outcome after surgery followed by indomethacin 
and radiotherapy (10), traumatic injury is a major trigger for FOP flare-ups and subsequent 
HO (3,29). Radiotherapy to prevent HO reoccurrence after surgery is a known and effective 
strategy in MOT (15,30,31), Indomethacin, an NSAID, is known for its post-operative 
preventative role in MOT (32). Usually, surgery is avoided in FOP because of the effects 
it can have on disease progression, although resection of HO has been performed to 
try and improve function and surgery may also be necessary in certain urgent 
conditions. If surgery is required, post-operative radiotherapy and/or NSAID treatment 
to prevent HO formation should be considered.
3. Patient tolerance or risk of non-radiotherapy side effects. 
Glucocorticoids are commonly used for the treatment of flare-ups, because of their 
anti-inflammatory effect. Although their effect on prevention of flare-ups and HO 
formation has never been rigorously tested, about half of the patients report an 
improvement in flare-up symptoms when treated with glucocorticoids (3). However, 
known side-effects are, among others, weight gain, proximal myopathy, glucose 




There is extensive experience with NSAIDs in FOP patients (24). About one third of 
patients use NSAIDs for flare-ups, although they can lead to gastrointestinal issues and 
renal toxicity (3). Radiotherapy should not be seen as a replacement for anti-inflammatory 
drugs, rather as a complementary treatment strategy to be considered in certain clinical 
situations and for selected patients.
Even though radiotherapy seems safe in FOP patients, one should keep in mind that post-
irradiation tissue damage (e.g. fibrosis) leading to (even minimal) mobility/function loss, can 
have a significant impact on the quality of life of patients. Patients are highly dependent on 
their remaining function and any disturbance can significantly affect daily life. Any 
intervention, including radiotherapy, should take this into account and, where possible, risks 
should be kept as low as possible.
In conclusion, the risk of HO induction by radiation in non-FOP patients is, as demonstrated 
by the few cases in our systematic review, very small and usually part of more widespread 
tissue damage. Based on available literature, radiotherapy induced HO formation does not 
seem to be a problem in non-FOP or FOP patients. As follow-up data are limited, radiotherapy 
for FOP patients should only be considered in specific situations, e.g. post-operatively after 
surgery or to reduce flare-up oedema when causing neurological deficits. As 18F-NaF is the 
only in vivo disease activity marker currently available, pre-treatment and follow-up imaging 
using 18F-NaF PET/CT should be considered to evaluate the effects of interventions, including 
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Supplementary table 1. Terms used in Pubmed to identify studies describing both radiotherapy and heterotopic 
ossification.
Search PubMed Query – December 6, 2018 Items 
found
#3 #1 AND #2 515
#2 “Radiotherapy”[Mesh] OR “radiotherapy”[Subheading] OR radiotherap*[tiab] OR 
radiati*[tiab] OR irradiati*[tiab] OR x ray therap*[tiab]
673905
#1 “Myositis Ossificans”[Mesh] OR “Ossification, Heterotopic”[Mesh] OR fibrodysplasia 
ossifican*[tiab] OR myositis ossifican*[tiab] OR ossifying myositis[tiab] OR ossifying 
fibrodysplasia [tiab] OR stone man[tiab] OR acvr1[tiab] OR fop[tiab] OR heterotopic 
ossifica*[tiab] OR ectopic ossifica*[tiab] OR pathologic ossifica*[tiab]
12684
Supplementary table 2. Terms used in Embase to identify studies describing both radiotherapy and heterotopic 
ossification.
Search Embase.com Query – December 6, 2018 Items 
found
#3 #1 AND #2 651
#2 ‘’radiotherapy’/exp OR radiotherap*:ab,ti,kw OR radiati*:ab,ti,kw OR irradiati*:ab,ti,kw 
OR (x-ray NEAR/3 therap*):ab,ti,kw
934801
#1 ‘ossifying myositis’/exp OR ‘heterotopic ossification’/exp OR (fibrodysplasia NEAR/3 
ossifican*):ab,ti,kw OR (myositis NEAR/3 ossifican*):ab,ti,kw OR (ossifying NEAR/3 
myositis):ab,ti,kw OR (ossifying NEAR/3 fibrodysplasia):ab,ti,kw OR ‘stone man’:ab,ti,kw 
OR acvr1:ab,ti,kw OR fop:ab,ti,kw OR (heterotopic NEAR/3 ossifica*):ab,ti,kw OR 
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Microarchitecture of heterotopic ossification 
in fibrodysplasia ossificans progressiva:
an HR-pQCT case series




It is challenging to study heterotopic ossification (HO) in patients with fibrodysplasia 
ossificans progressiva (FOP) due to the contraindication of invasive techniques (i.e. bone 
biopsies), which can trigger flare-ups. The aim of this case study was to assess mature HO 
at microarchitectural level non-invasively with high-resolution peripheral quantitative 
computed tomography (HR-pQCT). Depending on the patient’s mobility, HR-pQCT scans 
were acquired of peripherally-located HO and standard distal radius and tibia regions in 
two FOP-patients, a 33-year-old woman and a 23-year-old man, with the classical mutation 
(p.R206H). HO was located around the halluces, ankles and in the Achilles tendon. Standard 
HR-pQCT analyses were performed of the distal radius, tibia, and HO to quantify bone 
mineral density (BMD) and bone microarchitecture. Micro-finite element analysis was used 
to estimate failure load (FL). The outcomes were compared between HO and neighboring 
skeletal bone and with an age- and gender-matched normative dataset from literature. 
Bone parameters of the radius were within the interquartile range (IQR) of normative data. 
In contrast, in the tibiae of both patients, total and trabecular BMD were below the IQR, as 
were trabecular bone volume fraction, number, and thickness, cortical thickness, and FL. 
Trabecular separation and heterogeneity were above the IQR. Isolated HO in the Achilles 
tendon had a lower total, trabecular, and cortical BMD, trabecular bone volume fraction, 
and cortical thickness than the normative tibia data. Trabecular microarchitecture was within 
the IQR, and FL was approximately 10 times higher than of the neighboring tibia after 
accounting for areal differences. Other scanned HO could only be qualitatively assessed, 
which revealed coalescence with the neighboring skeletal bone, development of a neo-
cortex, and partial replacement of the original skeletal cortex with trabeculae. To conclude, 
isolated HO seemed microarchitecturally more comparable to reference tibia data than the 
peripheral skeleton of the FOP-patients. Also, HO and skeleton appear to be able to become 
one entity when contiguous. 
Keywords
Fibrodysplasia ossificans progressiva; Heterotopic ossification; Bone microarchitecture; 
Bone strength; High-resolution peripheral quantitative computed tomography




Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease that is characterized 
by the formation of heterotopic ossification (HO) in ligaments, tendons, and muscles (1-3). 
The formation of HO is often preceded by a clinical flare-up whose clinical signs are, among 
others, pain, redness, and swelling (3,4). The histology of these flare-ups developing into 
HO has previously been studied through biopsies that were obtained for other purposes, 
mainly to exclude malignancies in non-diagnosed FOP-patients (5,6). It is thought that, in 
the early stage of this HO development, the infiltration of inflammatory cells, such as 
lymphocytes, mast cells, and macrophages, causes cell death of the affected connective 
tissue. Proliferation of fibroblasts is thought to play a crucial role in the successive HO 
stage (7). Finally, the fibroproliferative tissue develops into cartilage before it develops into 
endochondral bone (5,6,8). 
Less is known about mature HO. The few histological and radiological case reports suggest 
HO to follow a normal endochondral process with deposition of bone matrix that visually 
appears indistinguishable from skeletal bone matrix with similar bone modeling and 
remodeling (9-11). When mature, HO seems to consist of both compact and lamellar bone 
structures and apparently normal bone marrow (12,13). In FOP-patients with the classic mutation 
(p.R206H), also the skeletal bone is assumed to develop normally despite developmental 
anomalies such as the frequently present shortened toes and the less frequently present 
short femoral neck and fusion of cervical facet joints (3). These case reports are mainly 
qualitative as quantitative comparison of mature HO and skeletal bone remains difficult. 
Furthermore, histological examinations of mature human FOP HO are limited due to a 
contraindication of invasive techniques, such as bone biopsies, in FOP-patients as these 
techniques can trigger a flare-up and consequently aggravate the disease (4,14). 
High-resolution peripheral quantitative computed tomography (HR-pQCT) may possibly 
alleviate the difficulty in investigating mature HO. This high-resolution imaging modality 
allows non-invasive and quantitative assessment of peripheral bones at the microarchitectural 
level, including quantification of geometry, density, and microarchitecture of the cortical 
and trabecular bone compartments and of the biomechanical properties of bone. Until now, 
HR-pQCT has mainly been used to study the distal radius and tibia (15), and to our knowledge, 
it has not yet been applied in FOP-patients. Therefore, the aim of this case study was to 
assess mature HO with HR-pQCT and to compare with neighboring skeletal bone. To evaluate 
whether the skeletal bone of the FOP-patients is representative, the FOP skeletal bone and 
HO were also compared with an age- and gender-matched reference. It was hypothesized 
that mature HO contains less and thinner trabeculae and a thinner cortex compared to 
neighboring skeletal bone because it is often non-functional and non-weight bearing. The 
skeletal bone was expected to show differences with an age- and gender-matched reference 
because of reduced mobility related to the disease. 
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2. Material and Methods
2.1 The patients
Two FOP-patients with the classical mutation (R206H), treated at the FOP Expertise Center 
of Amsterdam, underwent HR-pQCT imaging for this case study. Patient 1 is a 33-year-old 
woman who is ambulant: she can cover short distances, but she is not able to walk longer 
distances and to run. She is known with peripheral HO around both first metatarsals and 
in the left Achilles tendon. The peripheral HO has been present for over twenty years, and 
the patient has not noticed any flare-up or changes of this HO in the past five years. She 
has not been taking any glucocorticoids in the past twelve months but is on chronic non-
steroidal anti-inflammatory drug (NSAID) treatment because of chronic pain due to HO at 
several sites. Patient 2 is a 23-year-old man. Peripheral HO is located around both first 
metatarsals and both ankles, all formed after a surgical correction of the hallux valgus early 
in childhood. The HO has been present for over 15 years, and the patient has not noticed 
any flare-up or changes of this HO in the past five years. He is wheelchair dependent when 
covering longer distances. He has not been using glucocorticoids and NSAIDs in the past 
twelve months. The peripheral HO in the patients was identified by physical examination 
and earlier acquired computed tomography (CT) and [18F] sodium fluoride (NaF) positron 
emission tomography (PET)-CT. They resembled mature bone as defined by a density >200 
HU on CT and were not metabolically active as assessed by peak standardized uptake values 
on [18F]NaF PET/CT (16). Both patients have been participating in the LUMINA-1 clinical trial 
with Activin A blocking antibody Garetosmab for three and four months, respectively at the 
time of HR-pQCT-scanning. The HR-pQCT-scans were not obtained as part of this double-
blind placebo-controlled study. The patients signed the informed consent form to publish 
their data anonymously, and this form was approved by the Medical Ethics Review 
Committee of the Amsterdam UMC (Amsterdam, The Netherlands).
2.2 HR-pQCT imaging protocol
If mobility of the patients allowed proper and comfortable positioning, HR-pQCT scans were 
obtained using the second-generation HR-pQCT scanner (XtremeCT II, Scanco Medical, 
Switzerland) with standard clinical settings, defined by the manufacturer (X-ray tube voltage 
of 68 kV, intensity of 1460 mA, and integration time of 43 ms). For the distal radius and tibia, 
one 10.2-mm stack was scanned at the standard location according to the standard protocol 
starting 9.5 mm and 22.5 mm proximally from the radial and tibial endplate, respectively, 
and extending proximally. For the peripherally-located HO, customized 30.6-mm regions 
(three consecutive stacks of 10.2 mm each) were scanned to ensure full capturing of the 
HO. The scout view, as part of the standard HR-pQCT procedure, was used to confirm a full 
capturing. To scan the HO in the halluces and ankles, the patients were carefully positioned 
with the hip and knee in flexion and the foot in plantar flexion. During acquisition of all 
scans, the lower arm or lower leg was placed in a standard motion restraining holder, and 
foam was added to the holder when necessary to ensure the patient’s comfort. Quality of 
HR-pQCT to assess HO
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the scans was graded by the operator during scan acquisition by inspection of a single low-
resolution slice of each stack using the clinically used grading system provided by the 
manufacturer (17). A scan was repeated when the quality of at least one stack had a grade 
>3 out of 5. Acquisition of one stack takes two minutes, resulting in total acquisition time 
of two minutes for each radius and tibia scan and six minutes for each HO scan. Effective 
radiation dose is approximately 5 µSv per stack, leading to an effective dose of approximately 
5 µSv per radius and tibia scan and of approximately 15 µSv per HO scan. The scans were 
reconstructed with an isotropic voxel size of 61 µm, resulting in 168 consecutive slices per 
radius and tibia scan and in 504 consecutive slices per HO scan.  
2.3 Evaluation of the HR-pQCT scans
The peripherally-located HO were visually assessed by a musculoskeletal radiologist (BT) 
affiliated to the FOP Expertise Center; the isolated HO in the Achilles tendon of patient 1 
was also quantitatively evaluated as were the distal radius and tibia. For the quantitative 
analysis, the isolated HO was manually segmented, and the distal radius and tibia were 
segmented using an automatic contouring algorithm provided by the manufacturer of the 
scanner. Thereafter, standard methods were used to quantify bone geometry, density, and 
microarchitecture of the segmented HO and distal radius and tibia. Geometric parameters 
included total, trabecular, and cortical area (Tt.Ar, Tb.Ar, and Ct.Ar, respectively; [mm2]). 
Densitometric parameters included volumetric bone mineral density of the entire, trabecular, 
and cortical bone (Tt.BMD, Tb.BMD, and Ct.BMD, respectively; [mg HA/cm3]). 
Microarchitectural parameters included trabecular bone volume fraction (Tb.BV/TV, [-]), 
trabecular number (Tb.N; [mm-1]), thickness (Tb.Th; [mm]), separation (Tb.Sp; [mm]), and 
heterogeneity (Tb.1/N.SD; [mm]), and cortical thickness (Ct.Th; [mm]) and porosity (Ct.Po; 
[-]). Additionally, failure load (FL) was estimated of the segmented HO and distal radii and 
tibiae by means of micro-finite element (µFE-) modeling. Linear three-dimensional µFE-
models were generated by converting the bone voxels of the HR-pQCT scans to equally-sized 
brick elements, which were assigned a Poisson’s ratio of 0.3 and a Young’s Modulus of 8748 
MPa (18). An axial compression to 1% strain was then simulated along the longitudinal axis 
(i.e. compression with constraint of lateral expansion at the bone endings) to estimate FL, 
for which Pistoia’s criterion was used (19). For this estimation of FL, it was assumed that the 
HO experiences a tensile load in the direction of the calve muscles and thus in the direction 
of the compression load on the tibia, and simulating either tension or compression gives, 
apart from the sign, the same results in FE-modeling.  
The resulting values of the bone parameters from all analyses were compared to an age- 
and gender-matched normative reference group. This normative dataset was obtained in 
a general Canadian male and female population using the same generation HR-pQCT 






The patients’ mobility allowed acquisition of HR-pQCT scans of HO in the left Achilles tendon 
and around both metatarsals of patient 1 and around the right ankle of patient 2. The HO 
in the Achilles tendon was visible on the standard scan of the left tibia and required no 
separate scan. HR-pQCT scans could not be acquired of the halluces and left ankle of patient 
2 as he was not able to position his foot in plantar flexion due to ankle ankylosis. His right 
ankle could be scanned without plantar flexion of the foot, but with additional foam for 
comfort during scan acquisition. Due to the inability of both patients to properly position 
before the scanner, a distal radius scan could only be made of the left side of patient 1. 
Distal tibia scans could be obtained of the left and right tibia of both patients. All obtained 
HR-pQCT-scans were of good quality (≤ grade 3 for all stacks); therefore, none of the scans 
had to be repeated.
3.2 Evaluation of the distal radius and tibia  
A three-dimensional visualization of the scanned left radius and right tibia of patient 1 is 
shown in Figure 1. Geometry, density, microarchitecture, and FL of the dominant side, the 
left radius of this patient, were within the 25th-75th percentile (pctl), except for Ct.BMD that 
Figure 1. Three-dimensional visualisation of the scanned left radius (A) and right tibia (B) of patient 1, obtained 
with HR-pQCT. (A) Quantification revealed great resemblance of the radius of the FOP-patient to that of an 
age- and gender-matched reference group, except for cortical density that was higher in the FOP-patient. (B) 
Quantification revealed major dissimilarities with the age- and gender-matched reference group, especially in 
total and trabecular density (lower in the patient) and in trabecular and cortical microarchitecture. 
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was considerably higher (90th-98th pctl) (Table 1). At the tibia, both patients had a low Tt.BMD 
and Tb.BMD compared to the age- and gender-matched reference group (<2nd pctl) (Tables 
1 and 2). Trabecular microarchitectural parameters were below or above the interquartile 
range (IQR): Tb.BV/TV, Tb.N, and Tb.Th were lower (<2nd pctl, <25th pctl, and <2nd pctl, 
respectively), and Tb.Sp and Tb.1/N.SD were higher (>75th pctl and >90th pctl, respectively). 
Also FL of the tibiae of both patients was lower than normative values (<2nd pctl). In patient 
1, Ct.Ar and Ct.Th were lower in both tibiae (both <10th pctl) and Ct.BMD was in the lower 
half of the IQR. In patient 2, Ct.Ar and Ct.Th were <25th pctl in the right tibia and Ct.BMD was 
in the upper half of the IQR in both tibiae. 
Table 1. Bone parameters of the left distal radius and left and right distal tibia of patient 1, a 33-year-old female, 


















Geometry (Area; mm2) 
   Tt.Ar 247.7 25-75 - - 714.6 75-90 709.1 25-75
   Tb.Ar 192.9 25-75 - - 627.5 75-90 622.8 75-90
   Ct.Ar 58.2 25-75 - - 92.6 2-10 91.6 2-10
Density (BMD; mg HA/cm3) - -
   Tt.BMD 336.0 25-75 - - 205.3 <2 202.6 <2
   Tb.BMD 143.1 25-75 - - 100.9 <2 95.2 <2
   Ct.BMD 991.2 90-98 - - 934.8 25-75 955.5 25-75
Microarchitecture
   Tb.BV/TV (-) 0.187 25-75 - - 0.143 <2 0.127 <2
   Tb.N (mm-1) 1.442 25-75 - - 1.149 10-25 1.162 10-25
   Tb.Th (mm) 0.211 25-75 - - 0.209 <2 0.202 <2
   Tb.Sp (mm) 0.649 25-75 - - 0.858 75-90 0.855 75-90
   Tb.1/N.SD (mm) 0.225 25-75 - - 0.420 90-98 0.380 90-98
   Ct.Th (mm) 1.043 25-75 - - 1.078 2-10 1.013 <2
   Ct.Po (-) 0.002 25-75 - - 0.008 25-75 0.009 25-75
Mechanics (µFE)
   FL (kN) 2.68 25-75 - - 5.28 <2 4.88 <2
Abbreviations: Tt = total; Tb = trabecular; Ct = cortical; Ar = area; BMD = volumetric bone mineral density; Tb.BV/
TV = trabecular bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular 
separation; Tb.1/N.SD = heterogeneity of the trabecular network; Ct.Th = cortical thickness; Ct.Po = cortical 
porosity; FL =  estimated failure load.
*Percentile is based on comparison with an age- and  gender-matched reference from literature(18).
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3.3 Evaluation of heterotopic ossification 
The HO in the left Achilles tendon of patient 1 was isolated from the neighboring skeletal 
bone in the scanned region and could therefore be qualitatively as well as quantitatively 
evaluated (Figure 2). The HO constituted a clear cortex and trabecular structure. The cortex 
appeared thinner than in the neighboring left tibia, but a thickening was present in the axial 
middle of the scanned region of the HO. Results of the quantitative analysis of the isolated 
HO and neighboring left tibia are presented in table 3. In the isolated HO, Ct.BMD was below 
the IQR of the normative dataset (<2nd pctl), while it was within the IQR in the left distal tibia. 
Tt.BMD, Tb.BMD, and Ct.Th were below the IQR for both the isolated HO and left tibia. The 
trabecular microarchitectural parameters were within the IQR for the HO except for Tb.BV/
TV (10th-25th pctl), whereas for the left tibia, Tb.BV/TV, Tb.N, and Tb.Th were lower than the 
IQR (<2nd pctl, 10th-25th pctl, and <2nd pctl, respectively) and Tb.Sp and Tb.1/N.SD higher (75th-
Table 2. Bone parameters of the left and right distal tibia of patient 2, a 23-year-old male, including normative 
values of the distal radius of age- and gender-matched controls.
Tibia Left Value Percentile* Right Value Percentile*
Geometry (Area; mm2)
   Tt.Ar 849.5 25-75 831.3 25-75
   Tb.Ar 718.9 25-75 713.7 25-75
   Ct.Ar 136.4 25-75 123.3 2-10
Density (BMD; mg HA/cm3)
   Tt.BMD 229.1 <2 232.8 <2
   Tb.BMD 98.4 <2 113.9 <2
   Ct.BMD 932.5 25-75 936.9 75-90
Microarchitecture
   Tb.BV/TV (-) 0.1558 <2 0.172 <2
   Tb.N (mm-1) 0.855 <2 1.086 2-10
   Tb.Th (mm) 0.235 <2 0.233 <2
   Tb.Sp (mm) 1.170 >98 0.902 90-98
   Tb.1/N.SD (mm) 0.827 >98 0.403 90-98
   Ct.Th (mm) 1.510 25-75 1.318 10-25
   Ct.Po (-) 0.012 25-75 0.007 10-25
Mechanics (µFE)
   FL (kN) 8.21 <2 7.82 <2
Abbreviations: Tt = total; Tb = trabecular; Ct = cortical; Ar = area; BMD = volumetric bone mineral density; Tb.BV/
TV = trabecular bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular 
separation; Tb.1/N.SD = heterogeneity of the trabecular network; Ct.Th = cortical thickness; Ct.Po = cortical 
porosity; FL = estimated failure load.
*Percentile is based on comparison with an age- and  gender-matched reference from literature(18).
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90th pctl and 90th-98th pctl respectively). FL was approximately a factor ten lower in the HO 
than in the left tibia. It was low compared to normative values (<2nd pctl). Total bone area 
was approximately a factor ten higher in the HO than in the tibia. 
The HR-pQCT scans obtained of the other peripheral HO in both patients revealed fusion 
with the neighboring skeletal bone and could only be qualitatively analyzed. Figure 3 shows 
a three-dimensional image of the halluces of patient 1. As can be seen, HO was fused with 
the phalanx, and at several sites where HO had adjoined the phalanx, the initial cortex was 
replaced by trabeculae. The trabecular compartments of the HO and phalanx seemed to 
merge and were surrounded by a cortex of the HO. This neo-cortex appeared thinner than 
the initial cortex of the phalanx, whereas the trabeculae appeared thicker (data not shown). 
A similar pattern was found in the right ankle of patient 2 (Figure 4): there was fusion of HO 
with the tibia, fibula, and talus with partial replacement of the original cortex by trabeculae 
and a (neo-) cortex surrounding the fused bone structures. Also, enlargement of the distal 
tibia was observed. The HO adjoining the ankle bones seemed to contain relatively more 
cortical bone than the ankle bones and the other HO lesions inspected.
Figure 2. A) Distal (left) and proximal (right) slice of the HR-pQCT scan of the left tibia of patient 1, a 33-year-
old female FOP-patient, showing isolated HO in the Achilles tendon. Quantification showed dissimilarities 
between the HO and the patient’s tibia, especially in trabecular microarchitecture when compared to an age- 
and gender-matched reference. B) Four slices from distal (left) to proximal (right) of the HR-pQCT scan of the 
left tibia showing HO in the Achilles tendon. 
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Although all HO lesions analyzed by HR-pQCT had a density of >200 HU and thus resembled 
mature bone, HU was lower in these lesions than in neighboring skeletal bone that had a 
density of >350 HU. The only exception was the HO around the ankle, which had a 
considerable higher HU value than the surrounding talus, tibia, and fibula. 
Table 3. Bone parameters of the left distal tibia and isolated HO in the left Achilles tendon of patient 1, a 33-
year old female, including normative values of the distal tibia with age- and gender-matched controls. 
HO left Achilles tendon Left tibia
Geometry (Area; mm2) Value Percentile* Value Percentile*
   Tt.Ar 64.9 <2 714.6 75-90
   Tb.Ar 49.6 <2 627.5 75-90
   Ct.Ar 17.2 <2 92.6 2-10
Density (BMD; mg HA/cm3)
   Tt.BMD 271.9 10-25 205.3 <2
   Tb.BMD 142.1 10-25 100.9 <2
   Ct.BMD 656.7 <2 934.8 25-75
Microarchitecture
   Tb.BV/TV (-) 0.195 10-25 0.143 <2
   Tb.N (mm-1) 1.242 25-75 1.149 10-25
   Tb.Th (mm) 0.254 25-75 0.209 <2
   Tb.Sp (mm) 0.766 25-75 0.858 75-90
   Tb.1/N.SD (mm) 0.282 25-75 0.420 90-98
   Ct.Th (mm) 0.917 <2 1.078 2-10
   Ct.Po (-) 0.013 25-75 0.008 25-75
Mechanics (µFE)
   FL (kN) 0.530 <2 5.28 <2
Abbreviations: Tt = total; Tb = trabecular; Ct = cortical; Ar = area; BMD = volumetric bone mineral density; Tb.BV/
TV = trabecular bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular 
separation; Tb.1/N.SD = heterogeneity of the trabecular network; Ct.Th = cortical thickness; Ct.Po = cortical 
porosity; FL = estimated failure load.
*Percentile is based on comparison with an age- and  gender-matched reference from literature(18).
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Figure 3: Three-dimensional visualization of the scanned metatarsals of the right (A) and left (B) foot of patient 
1. The patient underwent surgery for the correction of a bilateral hallux valgus at the age of 1, resulting in HO 
at the operated sites. The pink color visualizes the sites with HO. It should be noted that, due to fusion, the 
exact border between HO and skeletal bone could not be established.
Figure 4. Nine two-dimensional slices of the HR-pQCT scan of a 30.6-mm region of the right ankle of patient 
2, a 23-year-old male FOP-patient, from distal (S1) to proximal (S502). (S1) shows the talus with HO attached. 
Original cortical layer of the talus seems disrupted at several sites where HO has fused. (S67 – S502) HO has 
also fused to the fibula. However, a thin cortical layer seems to be present throughout the series. (S201 – S502) 
HO has fused to the tibia, and as with the talus, the cortical layer is disrupted at several sites of the fusion. TIB, 
TAL, and FIB represent tibia, talus, and fibula, respectively. On the right, HO, increased cortical bone and the 
thinned cortex are visualized in blue, red and yellow, respectively. It should be noted that, due to fusion, the 
exact border between HO and skeletal bone could not be established.
Chapter 7
106
4. Discussion  
The aim of this case study was to assess peripherally-located mature HO and skeletal bone 
of two FOP-patients with HR-pQCT and to compare those with each other and with an age- 
and gender-matched reference group from literature. The HO assessed in both patients 
was found to merge with neighboring skeletal bone. The cortex of the skeletal bone at sites 
of fusion appeared to be replaced by trabeculae to form one new entity, constituting 
trabecular bone surrounded by a (neo-)cortex. Most bone parameters of the isolated HO 
in the Achilles tendon of one of the patients were found to be within the IQR of age- and 
gender matched reference tibia data, whereas most of the neighboring tibia were below or 
above the IQR. Bone parameters of the distal radius resembled the literature values, except 
for cortical BMD. 
To the best of our knowledge, this is the first study examining HO non-invasively and at a 
microarchitectural level in living FOP-patients. HO around the halluces and ankle of the 
patients was merged with the neighboring skeletal bone, and it appeared that a neo-cortex 
was formed surrounding the HO where it fused with the skeletal bone. However, thin lining 
of the original cortical layer of the skeleton was still visible at various regions, suggesting a 
yet incomplete coalescence. This may indicate that the fusion of HO and skeletal bone and 
associated remodeling is a slow process considering the presence of the HO for over 15 
years in both patients. The neo-cortex around the halluces appeared thinner than the 
original skeletal cortex, whereas HO around the ankle consisted of a relatively thick cortical 
layer, which is perhaps due to the weight-bearing function of the ankle and its associated 
HO. Both these fused HO and the isolated HO assessed in this case study showed a cortical 
and trabecular compartment, as do skeletal bones, which, in that respect, agrees with 
previous case reports suggested that HO of FOP-patients has a similar morphology as 
skeletal bone (6,10). However, these earlier publications have mainly investigated biopsies of 
early HO lesions that were taken in children for other reasons (6,12,13), while we investigated 
mature HO lesions as confirmed by CT. Furthermore, the use of HR-pQCT instead of histology 
enables quantitative evaluation of HO besides qualitative assessment, which may provide 
new insights into HO in FOP.
Today, quantitative assessment of the microarchitecture of HO is scarce. Most mice studies 
mimicking FOP and HO formation have not quantified HO microstructure despite the use 
high-resolution imaging modalities (e.g. µCT) (20-23). In humans, the only study quantifying HO 
at the microarchitectural level concerned, to our knowledge, an ex vivo µCT-study on bone 
biopsies of non-genetic HO. In that study, surgically removed HO at muscular tissue was 
analyzed, which revealed variations in microarchitecture between and within lesions and an 
affected strength of the HO lesions compared to skeletal bone (24). In contrast, we found FL 
of the isolated HO in the Achilles tendon to be approximately 10% higher than of the 
neighboring tibia when correcting for the difference in total bone area. This agrees with the 
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assumption in literature that the strength of HO in FOP is preserved, which is based on the 
observation that (stress) fractures of HO are not often seen in FOP-patients (25). The 
discrepancy in the findings on strength between the study on non-genetic HO and our case 
study on genetic HO may, among others, be caused by a different ossification process with 
distinct histological characteristics between genetic and non-genetic HO (26). Furthermore, 
HO in tendons may not be representative for HO in muscles as for example trauma-induced 
muscle HO in FOP appears to be driven through another progenitor lineage than HO formed 
in ligaments and tendons (27). This may also contribute to the qualitative differences found 
at the microarchitectural level between the trauma-induced HO around the ankle of patient 
2 and the spontaneously formed HO in the Achilles tendon of patient 1. Notably, the estimated 
FL in the isolated HO in the Achilles tendon is lower than peak forces that occur in the Achilles 
tendon during daily life in healthy individuals (e.g. 1.3-1.5 kN during walking; up to 4 kN during 
running and jumping (28-30)), which would suggest rupture of the Achilles tendon or fracture 
of the HO during such activities. However, such peak forces may not be reached in FOP-
patients due to their reduced ability or inability to fully perform these activities. 
Comparison of the quantitative evaluation of the HO in the Achilles tendon with the 
neighboring tibia showed that the microarchitectural parameters of the HO had better 
agreement with the age- and gender-matched reference than the left tibia. It is not known 
what may have caused this difference between HO and neighboring tibia. Possibly, a 
different mechanical stimulation may play a role, but study in larger datasets is needed 
before any conclusions can be drawn about possible microarchitectural differences between 
HO and skeleton. These microarchitectural differences could have contributed to the 10-% 
larger estimated FL of the HO compared to the tibia after accounting for areal differences. 
The comparison of the HO with the peripheral skeleton raises the question whether the 
skeletal bone of FOP-patients is comparable at the microarchitectural level to an age- and 
gender-matched reference (31). Unlike microarchitectural misbalances throughout the entire 
skeleton in other rare bone diseases, the microarchitecture of the analyzed radius of patient 
1 was found to be comparable to an age- and gender-matched reference population (32-35). 
The tibiae of both FOP-patients, in contrast, did show considerable deviations from age- and 
gender-matched normative data: total and trabecular BMD were lower, and the trabecular 
compartment consisted of less and thinner trabeculae in a more heterogeneously formed 
network. A reduced mobility or a changed mechanical loading in the FOP-patients could 
have contributed to these differences from the normative data, as could have the frequent 
glucocorticoid use of both patients (36). Research in larger datasets is needed to further 
investigate possible microarchitectural differences between the skeleton of FOP-patients 
and of the general population. 
This study has shown that HR-pQCT allows visualization and quantification of BMD, 
microarchitecture, and biomechanical properties of mature HO in FOP-patients in vivo. This 
imaging modality enables analysis of mature HO in more detail than other imaging 
modalities, while simultaneously exposing patients to a negligible amount of radiation. 
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Furthermore, it is non-invasive in contrast to bone biopsy for histological analysis; therefore, 
it does not trigger flare-ups as is the case with biopsy. Consequently, HR-pQCT may be an 
interesting technique for future research into mature HO in FOP, such as for sequential 
HR-pQCT imaging to study the development of mineralized HO during a flare-up or the 
effects of a study drug on mature HO. However, it is likely that the ability of FOP-patients 
to properly position before the gantry of the scanner is restricted as shoulders, elbows, 
hips, and knees are frequently ankylosed in these patients (4), which may limit scan acquisition 
and affect scan quality. The right distal radius of patient 1 and both distal radii and the right 
ankle of patient 2 could not be scanned for that reason. As a result, it may be challenging 
to find patients eligible for HR-pQCT scanning combined with the rarity of FOP and the 
restriction to peripheral bones as HO in FOP-patients mainly forms more centrally, while 
peripheral sites are often spared (1,4,37,38).
Several limitations of this case study have to be mentioned. First, we examined HO of two 
FOP-patients, which gives an interesting impression about the skeletal microarchitecture 
of bone in FOP-patients but does limit interpretation. Larger datasets are needed to draw 
conclusions on possible differences in BMD, microarchitecture, and strength between HO 
and skeletal bone and between skeletal bone of FOP-patients and an age- and gender-
matched reference population. Second, the estimation of FL using µFE-analysis and Pistoia’s 
criterion is only validated for the distal radius, and thus its accuracy is not known for HO, 
further limiting conclusions on the strength of HO compared to skeletal bone. Third, the 
two patients in this study were participating in a double blind placebo-controlled trial at the 
time of HR-pQCT imaging, and it is unknown whether they were on active treatment that 
could have influenced bone parameters. Finally, quantitative analysis of HO was limited to 
HO in the Achilles tendon of patient 1 as the other scanned HO were not isolated from the 
neighboring skeletal bone, which made it impossible to establish the exact border between 
the HO and the skeletal bone for segmentation of the HO. Nevertheless, qualitative analysis 
was possible for this HO. 
In conclusion, this case study showed that HR-pQCT allows non-invasive assessment of 
peripherally-located HO and distal radius and tibia in FOP-patients, which may provide new 
insights into skeletal and heterotopic bone in FOP-patients at the microarchitectural level. 
Isolated HO seemed microarchitecturally more comparable to skeletal bone from reference 
data than the peripheral skeleton of FOP-patients. Additionally, HO and skeleton appear to 
become one entity when contiguous. 
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Deterioration of pulmonary function:  






Fibrodysplasia ossificans progressiva (FOP) is a genetic disease characterized by the 
formation of heterotopic ossification (HO) in connective tissues. HO first develops in the 
thoracic region, before more peripheral sites are affected. Due to HO along the thoracic 
cage, its movements are restricted and pulmonary function deteriorates. Because 
development of HO is progressive, it is likely that pulmonary function deteriorates over 
time, but longitudinal data on pulmonary function in FOP are missing.
Longitudinal pulmonary function tests (PFTs) from seven FOP patients were evaluated 
retrospectively to assess whether there were changes in pulmonary function during aging. 
Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), total lung capacity 
(TLC), residual volume (RV) and diffusing lung capacity for carbon dioxide divided by alveolar 
volume (DLCO/VA) were included. In addition, HO volume along the thorax together with 
its progression as identified by whole body low dose CT scans were correlated to PFT data.
Per patient, aged 7-57 years at the time of the first PFT, three to nine PFTs were available 
over a period of 6-18 years. Restrictive pulmonary function, identified by TLC or suspected 
by FVC, was found in all, but one, patients. In three patients, TLC, FVC or both decreased 
further during the follow-up period. All, but one, patients had an increased RV. The DLCO/
VA ratio was normal in all FOP patients. Interestingly, FEV1 increased after a surgical 
intervention to unlock the jaw. In four out of five patients total HO volume in the thoracic 
region progressed beyond early adulthood, but no further decline in FVC was observed.
In conclusion, restrictive pulmonary function was found in the majority of patients already 
at an early age. Further studies are needed to assess whether the deterioration in pulmonary 
function is indeed age dependent.




Fibrodysplasia Ossificans Progressiva (FOP) is a rare, disabling genetic disease, which is 
characterized by the formation of heterotopic ossification (HO) in muscles, ligaments and 
tendons(1,2). HO often is preceded by a flare-up, an inflammatory process with, as yet, 
unknown pathophysiology. In most cases the first flare-ups occur around the age of six, 
often involving neck and upper back(3). Thoracic HO immobilizes the thoracic cage, restricting 
normal expansion of the lungs(4-7). As a result, patients are dependent on diaphragmatic 
breathing as the diaphragm is spared in FOP(7). Mean life expectancy of patients with FOP 
is limited to 40-50 years of age, with cardiorespiratory complications as the major cause of 
death(4,5). Some cross-sectional studies have shown restricted pulmonary function in FOP, 
which was attributed to limited chest mobility(6-8). It is not known, however, whether 
pulmonary function declines further while the disease is progressing. Longitudinal 
pulmonary function tests (PFTs) could give more insight on the impact of both HO volume 
and its progression on pulmonary function(9).
To the best of our knowledge, longitudinal data on pulmonary function in FOP patients have 
not been studied yet. It can be hypothesized that a decline in pulmonary function, if present, 
is related to (chronic) progression of HO around the thoracic cage. The aim of this study 
was therefore to assess the relationship between temporal changes in PFTs and volumetric 
HO changes along the thoracic area.
2. Methods
FOP patients treated at the FOP Expertise Center of Amsterdam UMC were included if 
successive PFTs were available between 1995 and 2019. In addition to PTFs obtained at the 
Amsterdam UMC, test results from referring centers were also included in the analysis.
Furthermore, whenever available, whole body low dose computed tomography (WBLDCT) 
scans were used to assess volume and progression of HO in the thoracic area and to 
evaluate structural changes within the lung parenchyma. 
The Medical Ethics Review Committee of the Amsterdam UMC, Vrije Universiteit Amsterdam 
approved the study. All patients signed informed consent for the analysis and anonymous 
publication of their data.
2.1 Pulmonary function tests
PFTs were obtained during yearly follow-up visits at Amsterdam UMC. Before 2014, 
spirometry, body plethysmography and single-breath transfer factor of the lung for carbon 
monoxide (DCLO) were measured using VMAX equipment from SensorMedics (Yorba Linda, 
CA, USA). From 2014, the Sentrysuite v.2.19 spirometry instrument (Carefusion, San Diego, 
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California, USA) and the Vyntus body plethysmograph (Vyaire Medical, Mettawa, Illinois, 
USA) were used. Static lung volumes of patients who were unable to enter the 
plethysmograph because of wheelchair dependency, were assessed by nitrogen washout 
on the VMAX equipment and by helium wash-in on the SentrySuite instrument. The following 
pulmonary function parameters were measured: forced vital capacity (FVC), vital capacity 
(VC), forced expiratory volume in one second (FEV1), residual volume (RV), expiratory reserve 
volume (ERV) and total lung capacity (TLC). In addition, lung diffusion was assessed by 
measuring diffusing capacity for carbon dioxide (DLCO) where DLCO was divided by alveolar 
volume (DLCO/VA). Reference values used for static and dynamic lung parameters were 
taken from the Global Lung Function 2012 Equations(10). For DCLO and DCLO/VA the 
guidelines of the Global Lung Function Initiative 2017 were used(11). FVC, TLC, FEV1, DLCO 
and DLCO/VA were expressed as percentage of predicted, based on gender, height and 
ethnicity according to those guidelines (10,11). For all measures, a percentage of predicted 
below 80% was considered deviant and the Tiffeneau index (FEV1/FVC) was considered 
deviant when below 70%(10,11).
2.2 Low dose CT-scans
Low-dose CT scans, acquired at 120 kV with a tube current ranging from 30 to 60 mAs, were 
assessed for structural abnormalities in lung parenchyma. CT scans were included when 
performed within either seven days prior to or one month after PFT. Images were analyzed 
by both a nuclear medicine specialist (PR) and a pulmonologist (AB) to assess parenchyma, 
pulmonary vasculature, pleurae, bronchi and heart size. Both, PR and AB, evaluated lung 
parenchyma blinded to the PFT results.
In addition, consecutive whole body low-dose CT scans (WBLDCT) were analyzed to identify 
HO lesions throughout the body and around the thoracic area. These HO lesions were 
identified and analyzed manually in order to calculate their volumes in successive images. 
Both readers (BT and EB) were blinded to the PFT of the patient. The association between 
HO volume of the total body, and HO within the thoracic area or the thoracic back and 
pulmonary function was statistically assessed. In addition, correlation between progression 
of HO in the thoracic area (chest) and decline in pulmonary function was evaluated. 
Moreover, the presence and a kyphosis and scoliosis was assessed using the available CT-
scans. Both the scoliosis and kyphosis angle was assessed using Cobbs Angle (12).
 
2.3 Statistical Analysis
Statistical analyses were performed using SPSS Statistics for Windows, (IBM, version 24.0, 
Armonk). The Spearman’s rho was used to assess correlations between HO volumes and 
change in PFT parameters.




Longitudinal PFTs of seven FOP patients were included in the study. All patients, except one, 
had the classic mutation (R206H). Demographics of the patients are presented in table 1 
and 2. The patient with the variant Q207E did not differ phenotypically from those with the 
classic mutation. All patients exhibited the classical clinical features of FOP with progressive 
HO formation. During flare-ups all patients underwent standard therapy with corticosteroids 
and non-steroidal anti-inflammatory drugs. Unfortunately, the frequency of flare-ups and 
drug treatments over the years had not been recorded.  One patient (patient 004) is a 
smoker, with 5 pack years up to the end of the included period. 
In total, 37 PFTs were included in the analysis. Of these PFTs, 12 were obtained in childhood 
(<18 years of age). Per patient, three to nine PFTs were available over a period of six to 
eighteen years. The age at which the first pulmonary function was obtained ranged from 7 
to 57 years (table 1). 61% of all the PFTs were obtained at Amsterdam UMC. In two patients, 
tests were performed in other centers.
In five patients at least two WBLDCT scans were available during the observation period to 
relate HO progression in the thoracic region with pulmonary function. 
For all 37 PFTs, FEV1 and FVC were available, while TLC was only measured in 20 of the 37 
PFTs (from 6 patients). Diffusion capacity was measured in 15 of the 37 PFTs from six 
patients. 
Table 1. Baseline characteristics and available data of the included FOP patients
Sex Mutation Age* Follow-up 
 (years)




001 ♂ R206H 12   8 27.2 6 Yes
002 ♀ R206H 35   8 13.3 3 Yes
003 ♀ R206H 21   6 20.2 4 Yes
004 ♂ R206H 57 11 26.3 8 No
005 ♂ R206H 21   6 24.2 4 No
006 ♀ Q207E 14   8 27.2 3 Yes
007 ♀ R206H   7 18 20.5 9 Yes
* at the time of the first pulmonary function test. 
** Highest BMI measured during the follow-up period
Abbreviations: FOP = fibrodysplasia ossificans progressiva; BMI = Body Mass Index; PFTs = pulmonary function 




3.1 Spirometry (FVC, VC, FEV1) 
FVC was below 80% of predicted in all patients irrespective of age and was already <80% in 
the youngest patient tested at the age of seven. FVC deteriorated over time in three of the 
seven FOP patients with a decline already in childhood (Figure 1). In two of these patients, 
worsening continued into young adulthood, up to the age of twenty-three. For two other 
patients, also followed in their twenties, FVC did not increase or decline during observation. 
For the oldest two patients in this study, followed from the age of 57 to 68 years and 35 to 
43 years, respectively, both absolute and percentage of predicted values for FVC remained 
stable. VC was congruent with FVC for all patients throughout the follow-up period. 
FEV1/FVC, also known as the Tiffeneau index, was below 70% of predicted in two patients, 
aged 18 and 68 years old (Tiffeneau of 68% and 65%, respectively). For all other patients 
the Tiffeneau index was >70%, ruling out any obstructive component. Interestingly, one 
patient who underwent jaw surgery experienced an increase in the Tiffeneau index from 
70% to 95% following surgery. The increased Tiffeneau index resulted from an increase in 
FEV1 (from 46% to 64%), possibly related to the slight improvement (3mm) of mouth opening 
(supplemental data, figure 1). FVC and VC remained stable pre- and post-operatively. In 
addition, also RV did not change due to the increased mouth opening.  The Tiffeneau index 
in five patients with and two patients without jaw ankyloses showed no obvious difference 
(65-93% vs 91-94%, respectively).
3.2 Static Lung Volumes (TLC, RV, ERV) 
TLC follow-up data were available for six patients. For one patient, only one measurement 
was available. A low TLC, indicating restrictive lung function (below 80% of predicted) was 
observed in five of the six patients. One patient with a low FVC and VC, appeared to have a 
normal TLC (Figure 1).
Table 2. Demographics of the included FOP patients














001 5 5 no ambulant 10 n/a
002 3 UNK yes Wheelchair bound (19) 67 60
003 10 5 no ambulant n/a n/a
004 12 UNK no Wheelchair bound (48) 44 50
005 6 UNK no Wheelchair bound (21) n/a 55
006 6 6 no Wheelchair bound (20) 60 n/a
007 6 6 no Wheelchair bound (18) n/a 20
*Kyphosis and scoliosis angles of the cervical and thoracic spine only were calculated, as this would impact 
pulmonary function. 
Age in years, angles in degrees. 
Abbreviations: UNK = unknown; n/a = not applicable / absent
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Figure 1. Longitudinal Pulmonary function 
test data of FOP patients
A decrease in FVC was seen in patient 001, 
006 and 007. The decline was already seen 
in childhood and early adolescence. TLC 
decreased in patient 001 and 007. The 
discrepancy between FVC and TLC in patient 
003 was caused by an increased RV/TLC-
ratio. This ratio was increased compared 
to predicted in all patients. Furthermore, 
FEV1 decreased over time in patient 001, 
006 and 007. Patient 003 regained a few 
millimeters mouth opening after surgery, 
with an increase of FEV1 as result. TLC, 
FVC and the RV/TLC-ratio did not change 
due to the increased mouth opening. 
Abbreviations: FOP = fibrodysplasia ossificans 
progressiva; FVC = forced vital capacity; TLC 
= total lung capacity; RV = Residual Volume; 




Deterioration of TLC during the observation period was observed in two patients during 
childhood and early adolescence. TLC in one patient decreased until the age of 19 and in 
the other patient between the age of 9 and 23. After the age of 23, no decline in TLC was 
found, but it should be noted that this is based on data of only two patients who were 
followed for up to 2 years after stabilization of TLC. For the two oldest patients, TLC follow-
up data were not available. 
The RV to TLC ratio was increased in five of the six patients (Figure 1). The ratio ranged from 
125-200% of predicted. The increase in mouth opening after surgery, did not result in 
normalization of RV. However, it did result in an increased volume of air that could be 
exhaled forcibly (ERV). Prior to surgery the ERV for this particular patient was 0.86L, which 
increased to 1.16L after surgery. For all other patients ERV ranged between 0.74L and 0.1L. 
 
3.3 Diffusing capacity (DLCO and DLCO/VA) 
DLCO was available for six patients and between 40-60% of predicted in five patients). The 
patient who underwent oro-maxillary surgery showed an no increase in DLCO after surgery. 
Also, no obvious difference in DLCO was found between patients with and without jaw 
ankyloses (45-98% vs. 39-46%, respectively). DLCO was corrected for alveolar volume (DLCO/
VA), diffusion was >80% for all six patients.
3.4 Lung parenchyma
Low-dose CT scans to evaluate lung parenchyma were available for all seven patients. Five 
showed a highly deformed thoracic cage, while it was nearly normal in the other two 
patients. The presence and severity of kyphosis and scoliosis are presented in table 1.  These 
two patients were 20 and 24 years old. Both had normal lung parenchyma, no pleural 
thickening or cardiomegaly. Three of the five patients with a deformed thorax showed 
intrapulmonary abnormalities: one had a partial atelectasis of the lower left lobe of ≈ 330 
mL, occupying 4% of the total lung volume. One had mild ground-glass opacity at the age 
of 22. There were no abnormalities in the parenchyma or pleurae. One patient, aged 65, 
had a minimal consolidation (3mm), which is currently being followed by high resolution CT 
according to the Fleishner criteria(13).
3.5 Heterotopic ossification 
In five patients successive LDWBCT-scans over a period of 6-26 months were available. 
Neither total body HO volume, HO volume within the thoracic area, nor HO volume along 
the thoracic back were significantly correlated with any of the PFT parameters (supplemental 
data). HO progression in the thoracic area was seen in four patients and ranged from 5 to 
11 mL in 6 to 26 months. The most prominent progression in the thoracic area with an 
increase in HO of 11 mL in 6 months was accompanied by stable TLC, FVC and DLCO/VA 
(Figure 1). Including all five patients for whom successive CT scans were available, no 
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association was found between HO expansion and FVC changes over this short period of 
time (spearman’s rho = -0.2; p=0.7). In addition, no association was found between total HO 
volume, thoracic HO volume and the PFT parameters (supplemental data).
4. Discussion
Thirty-seven PFTs were analyzed in a longitudinal cohort of seven FOP patients to determine 
whether lung function over a period of 6 to 18 years was associated with HO volume and 
HO progression in the thoracic area. A restrictive pulmonary function was found in all but 
one patients. This restriction in pulmonary function deteriorated over time during childhood 
and early adolescence, but a further decline later in life was not observed. No significant 
obstructive pulmonary function was found, nor a relationship between the degree of 
pulmonary function impairment and thoracic HO volume. 
FEV1 is the simplest parameter to obtain a rapid assessment of lung function. A reduced 
FEV1 value usually is related to the degree of obstructive pulmonary function(14,15). In the 
current cohort, significantly reduced FEV1 values were found in all patients, but in the 
presence of a normal Tiffeneau index. The reduced FEV1 value can therefore be attributed 
to reduced lung volumes in FOP patients. An ankylosed jaw, often seen in FOP, affects FEV1 
values. In one the present patients, FEV1 increased by 40% after surgical unlocking the 
ankylosed jaw. A similar effect on FEV1 was found in possibly the only published study on 
this topic, assessing the effect of maxillomandibular fixation in healthy subjects on 
pulmonary function, where FEV1 decreased with approximately 20% as a result of the 
maxillomandibular fixation(16). In addition, a study simulating the effect of upper airway 
obstruction using mouth pieces with orifices of different diameters, found that FEV1 
progressively worsened with decreasing diameters(17). Therefore, although FEV1 was 
decreased in most of the present FOP patients due to decreased lung capacity, jaw occlusion 
also may play a role in the severity of FEV1. Obstruction of the upper airways also seems to 
influence other values of the pulmonary function (e.g. ERV).
All patients had reduced FVC and VC, which suggests the presence of restrictive lung 
function. It should be noted, however, that to confirm restrictive pulmonary function initially, 
assessment of total lung volume (TLC) is essential, and therefore the use of an additional 
test is required(14). In the present study, a normal TLC was only observed in one patient, 
despite a suggestive restriction based on FVC (57%). This may be explained by an increased 
RV, seen in all but one of the patients, and which represents the difference between TLC and 
VC. The underlying mechanism of an increased RV in FOP patients could be the inability to 
fully exhale, as confirmed by ERV, possibly due to completely ankyloses of the thoracic cage. 
An increased RV is also seen as an early pulmonary abnormality in neuromuscular 
diseases(18). In later stages, muscle weakness leads to a restrictive pulmonary function. 
Whether this process also occurs in FOP patients, could not be confirmed with the current 
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limited dataset. Remarkably, RV in the 65-year old patient was within the normal range. 
With aging, RV is thought to increase as a result of stiffening of the thoracic wall(19). FOP 
patients will not be susceptible for this stiffening as they are already completely ankylosed, 
explaining the increased, but stable, RV throughout the observed period in the current 
cohort. As RV does not seem to fluctuate over time, FVC can be used to monitor pulmonary 
function after initial confirmation of restriction by TLC. 
The restrictive pulmonary function, as seen in the present study, is in concordance with 
findings of two cross-sectional studies(6,7). These two studies included 21 and 15 FOP patients. 
respectively. Unfortunately TLC values were not obtained. Although the age of the patients 
studied by Kussmaul et al. ranged from 5-55 years, values were only presented for the entire 
group, making it impossible to compare pulmonary function of younger patients with that 
of older patients(6). On the other hand, On the other hand, in their study on adult FOP 
patients, Connor et al. concluded that age had no effect on the degree of restriction, as FVC 
did not differ between age groups (7).  Whether there is a plateau in the degree of 
deterioration and, if so, at which age this would be reached, could not be determined in the 
present study, as only three patients were followed from childhood to adolescence with 
only a limited number of follow-up years.
Longer follow-up and more structural PFTs are needed to confirm whether pulmonary 
function indeed stabilizes at a certain age. It is assumed that the restrictive pulmonary 
function is the result of both malformed costovertebral joints and chest wall deformities 
due to asymmetrical HO formation along the spine and thoracic cage(4). One could argue 
that the severity of the chest wall deformity (kyphosis or scoliosis) should have an impact 
on the restriction of the thoracic cage. Two of the patients with relatively mild thoracic 
deformities did, however, show severe restricted pulmonary function. Therefore, thoracic 
deformity alone does not fully predict abnormality of lung function.  In addition, the location 
of HO, especially whether HO is located near crucial joints or not, might also be important. 
Also, pulmonary function hardly appears to deteriorate later in life, it seems that the amount 
of HO formed in the thoracic area at younger age may already be sufficient to restrict 
pulmonary function and that it is not affected by further (later) progression of HO. In an 
attempt to further investigate this, effects of total amount and chronic growth of HO in the 
thoracic region and pulmonary function were assessed, but neither showed a relationship 
with the pulmonary function nor its decline. Moreover, previously it has been shown that 
chest wall expansion does not deteriorate further after the age of 15(6). However, lifetime 
PFT data from FOP patients are not available yet. 
Life-long PFT data and WBLDCT images will be needed to evaluate the clinical relevance of 
mild abnormalities of the lung parenchyma, which were seen in two of the patients in the 
present study. Restrictive pulmonary function may lead to relaxation atelectasis, which may 
reduce TLC. In the present study no distinction was made between restriction caused by an 
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immobile thorax or by atelectasis. Atelectasis observed in one of the patients covered only 
a small portion of total TLC and, therefore, thoracic stiffness is likely to be the most important 
cause of restrictive pulmonary function in FOP. In an attempt to prevent atelectasis, 
respiratory muscle training, using a hand-held unit with tubing and a connected rebreathing 
bag, could be considered in an attempt to maintain adequate ventilation of the alveoli(20). 
In addition, if oxygen therapy is considered, the patient should be monitored closely to 
prevent hypercapnia and hyperoxia related damage to airways or pulmonary parenchyma(5), 
especially as, in general, patients with a severely affected, immobilized thoracic cage already 
have a degree of hypercapnia(21). 
The strength of this study is the long follow-up period of a group of FOP patients. The main 
limitation of the present study is the inability to relate pulmonary function tests to clinical 
data, due to incomplete documentation. Also, given that data were acquired within the 
context of standard patient care, PFTs had not been obtained regularly and not all 
parameters were obtained. In addition, measuring equipment was not standardized over 
time or between different centres. throughout time various measuring instruments have 
been used, and, data of other centers are included of which the measuring instruments are 
unknown. 
In conclusion, longitudinal PFTs confirmed restricted pulmonary function in FOP patients 
already at young age. TLC is necessary to confirm the restrictive component in FOP patients 
initially, as increased RV may affect FVC. In addition, it should be noted that FEV1 values are 
diminished due to small lung volumes, but might also be affected the jaw ankylosis. Neither 
total volume of HO nor progression of thoracic HO seemed to affect pulmonary function 
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The aim of the work described in this thesis was to gain more insight in the development, 
progression and complications of heterotopic ossification (HO) in fibrodysplasia ossificans 
progressiva (FOP). Knowledge about the course of HO is scarce, despite the discovery of a 
causative genetic mutation in 2006. There are several reasons for this poor understanding 
of HO, such as the contraindication of invasive techniques to study HO as it may cause 
exacerbation of disease; the lack of a representative mouse model until very recently, and 
the rarity of the disease.
As a (blood)marker to measure disease activity was not available at the onset of the work 
described in this thesis, the main purpose was to investigate whether imaging techniques 
could play a role. More specifically, the use of [18F] sodium fluoride (NaF) Positron Emission 
Tomography (PET) / Computed tomography (CT) was investigated as, at least in theory, this 
technique can be used to visualize and measure metabolic activity of bone. In addition, the 
additional diagnostic value of Magnetic Resonance Imaging (MRI) in FOP was studied. Both 
these imaging techniques were used to investigate whether FOP disease is only active during 
flare-ups, the course of FOP disease activity, and whether there are different developmental 
stages of HO. In addition, effects of different (traumatic) therapies on HO development were 
evaluated. The structure of matured HO was studied using a novel imaging technique, HR-
pQCT, and, finally, effects of progressive HO on vital organs were evaluated using sequential 
pulmonary function tests. 
Summary of main findings
In chapter 2, a severe spontaneous flare-up that led to wheelchair dependency of a FOP 
patient was described and followed using blood parameters and sequential 18F-NaF PET/CT 
scans. Indeed, for the first time, it was shown that disease activity could be visualized and 
measured. Interestingly, the site of the flare-up was found to be only partially take up 
18F-NaF. This biologically active site showed to be associated with developing HO on a follow-
up CT scan. In contrast, none of the measured blood parameters was correlated with disease 
activity. It was concluded that 18F-NaF PET/CT provides the an early disease marker in FOP, 
able to predict whether a flare-up is ossifying or not.
In chapter 3 it was investigated whether FOP disease activity is only present during flare-
ups. Sequential CT scans of five FOP patients were used to measure HO volumes over time 
and, separately, sequential 18F-NaF PET scans were analysed to identify biological activity of 
all HO lesions. These analyses revealed that, during the study period, only those HO lesions 
that showed 18F-NaF uptake above a certain threshold, far above normal bone remodelling, 
progressed over time. This finding led to the conclusion that, next to acute flare-ups, FOP 
also has a chronic component, leading to slow progression of existing HO in the absence 




As there is no radiation exposure involved, the next question, addressed in chapter 4, was 
whether MRI could be used to identify the different aspects, i.e. flare-ups and chronic 
progression, of FOP disease activity. This was tackled by evaluating the presence and 
intensity of oedema on MRI of patients with FOP. MRIs were either obtained for yearly 
follow-up (whole body MRI) or because of suspicion of a flare-up. Oedema found by MRI in 
four patients was compared with disease activity obtained by 18F-NaF PET. Flare-ups were 
indeed accompanied by either moderate or severe oedema. However, oedema was also 
found at sites without metabolic activity on 18F-NaF PET, and those sites did not reveal any 
ossification on follow-up CT scans. Whether the presence of this oedema could be an 
expression of an early inflammatory phase in FOP needs to be further addressed in future 
studies. Lastly, the chronic phase, as described in chapter 3, was not accompanied by 
oedema and could therefore not be identified by MRI. 
In chapter 5 the effect of a surgical procedure on both flare-ups and the chronic component 
of disease activity was evaluated using both a systematic review of the literature and a 
separate case study. The systematic review of surgery on extremities in FOP revealed that 
in >80% of the cases limb surgery was complicated by HO formation. Although surgical 
procedures are contra-indicated in FOP, in the case report surgery was the last resort in the 
treatment of chronically infected ulcers of the right foot and lower leg. A through-knee 
amputation was performed with surprisingly only minor HO formation afterwards. In this 
chapter is was shown that, if life threatening, a surgical procedure could be considered if 
performed in a multidisciplinary team with FOP expertise.  
In chapter 6 the effect of radiotherapy on flare-ups and chronic disease progression was 
evaluated using 18F-NaF PET/CT. Also, a systematic review of the effect of radiotherapy on 
HO formation in FOP patients was performed. This review revealed that previously only low 
dosages of radiotherapy (≤10 Gray) had been administered to FOP patients. Some authors 
suggested a beneficial effect of radiotherapy on symptoms, but its effect on halting HO 
formation has remained unclear. In addition, follow-up was in most cases insufficient. In 
the case study, a patient underwent a total of 54 Gray for a basal cell carcinoma (BCC) of 
the lip. Despite tissue damage that was clearly visible at the site of radiotherapy, no HO 
formed at the irradiated site. Neither did the treatment result in increased disease activity 
elsewhere. This case illustrates the safe application of curative radiotherapy for cancer 
treatment in a FOP patient. Furthermore, there might be a potential protective role of 
radiotherapy upon HO formation as found in the literature. 
In chapter 7 the micro-architecture of HO was compared with that of skeletal bone. Both 
HO and skeletal bone of two FOP patients were evaluated with the use of the HR-pQCT, a 
novel imaging technique. The HR-pQCT is a non-invasive, low-radiation method for assessing 
bone microarchitecture and volumetric bone mineral density (BMD) in cortical and trabecular 
compartments. Separate CT scans showed that overall density of assessed HO-lesions was 
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comparable with that of mature bone. HR-pQCT, however, revealed that cortical density of 
HO was lower compared with neighbouring skeletal bone, whereas trabecular density was 
increased. Interestingly, at some sites, it was found that HO and its adjacent skeletal bone 
had fused with disappearance of the original cortical layer. But, at various sites the original 
cortical layer was still intact, even after 20 years, implicating that this fusion of HO and 
skeletal bone is a very slow process. 
In the last chapter of this thesis, chapter 8, the natural course of pulmonary function in 
FOP patients and its relationship with HO volume was investigated. Seven patients with in 
total thirty-seven pulmonary function tests over a period of 6-18 years were included 
retrospectively. Although previous studies have assumed restrictive pulmonary function in 
all FOP patients, this was not present in one of the patients included. Forced vital capacity, 
used in previous studies, was affected by the inability to fully exhale, which leads to an 
increased amount of air in the lungs after exhalation (residual volume). This increased 
residual volume, in turn, leads to an incorrect conclusion of restrictive pulmonary function 
. Therefore, total lung capacity should be obtained for the initial assessment of the 
pulmonary function in FOP. When present, restrictive pulmonary function could already be 
identified early in childhood and worsened into early adulthood. Later in life, pulmonary 
function seemed to remain stable. The degree of restriction was not correlated with the 
volume and progression of HO along the thoracic cage. 
Discussion
18F-NaF PET/CT is a non-invasive tool to identify and quantify both active and chronic disease 
activity in FOP patients. The presence of chronic disease might offer an explanation for the 
clinical phenomenon of progressive immobilization of FOP patients in the absence of flare-
ups(1). Disease activity of the chronic component of FOP is significantly lower than the activity 
measured during a flare-up, consistent with the slower growth of HO during the chronic 
phase. As nearly all FOP patients fit within the scanner, this technique can be used in clinical 
practice to alter therapeutic decisions. Furthermore, follow-up 18F-NaF PET/CT scans could 
increase knowledge about the natural course of the disease, which still is not completely 
understood. In addition, this imaging technique seems to be of great value for clinical trials. 
Especially for those trials designed to halt HO formation after a flare-up, the 18F-NaF PET/
CT could be of great value. In fact, the first clinical trial in FOP in which Palovarotene was 
tested, was to halt HO formation by inhibiting the chondrogenesis(2). Unfortunately, in 2014 
the value of 18F-NaF PET was not known yet, and therefore crucial information on the initial 
fate of the flare-up was missed by using CT only. In 2017, another phase II clinical trial was 
initiated, with 18F-NaF-uptake as a primary endpoint. Garetosmab, an Activin A antibody, 
was tested as a therapeutic drug to reduce disease activity of both the flare-ups and the 




The 18F-NaF PET/CT-scan exposes the patient to a relatively low dose of radiation by using 
a low dose whole body CT-scan. With 18F-NaF PET/CT, the radiation dose to the patient is 
the combination of the radiation dose from the 18F-NaF and the radiation dose from the CT. 
Based on the injection of 87 MBq 18F-NaF to an adult patient of 70kg, the effective dose is 
2,1 mSv for the 18F-NaF . The effective dose for a whole body CT used for attenuation 
correction and correlation with the PET is variable and depends on a number of factors. For 
a whole body lowdose CT the effective dose may be 2.7 msv. Hence, the total effective of 
the 18F-NaF PET/CT procedure ≈ 5 mSv(5).Due to increased risk of malignancies, physicians 
should take the radiation exposure into account, especially when there is need for sequential 
scanning due to recurrent flare-ups or participation in a trial. The malignancy most 
associated with radiation exposure is leukaemia, with a relative risk of 3.8 in children who 
received >30mSv compared to those who received <5mSv(6). Due to the low incidence of 
leukaemia, the increased risk will mean in practice one extra case of leukaemia among 
10.000 children. 
It is important that centres follow the guidelines of the European Association of Nuclear 
Medicine (EANM) for correct dosing and injection time(5), in order to be able to compare the 
findings with each other. However, even though identical protocols are used, there will be 
a slight inter-scanner variation(7). Therefore, reference values might need to be recalculated 
per centre. Lastly, 18F-NaF PET/CT-images might be challenging to read, due to the highly 
distorted anatomy of the skeleton. Also, special adjusted programs for PET, CT and combined 
analysis are needed to manually segment and analyse the structures. Thus, preferably, 
these scans are performed in collaboration with an FOP expertise centre. So, even though 
a marker for disease activity was found with the 18F-NaF PET/CT it will be still essential to 
find a simple, safe and widespread accessible marker. In the search for such a (blood)marker, 
18F-NaF PET/CT could be used as the golden standard for identifying ossifying disease activity, 
as increased 18F-NaF uptake precedes active ossification. In the past, blood markers were 
related to clinical signs, i.e. flare-ups, and thus lacked quantification(8,9).
Unfortunately, MRI was not found as valuable as 18F-NaF PET/CT in assessing acute and 
chronic ossifying disease activity. In particular, MRI was unable to detect chronic FOP disease. 
However, regardless of its fate, all clinical flare-ups, i.e. active disease, coincided with oedema 
and thus, in clinical practice, MRI can be used to distinguish a flare-up from other diagnoses. 
Unfortunately, it is not possible to precisely quantify the severity of oedema. As both 
presence and absence of oedema do not appear to be correlated with HO development or 
HO progression, the value of MRI in FOP will remain limited, especially for clinical trials. 
Nevertheless, MRI may be able to detect a potential very early phase of disease activity. 
Whether oedema in this early stage is triggered by trauma or develops spontaneously is 
still to be investigated. In addition, it still has to be determined whether and how this oedema 
resolves or perhaps develops into a flare-up. These questions can only be answered by 
continuing to follow FOP patients through MRI and 18F-NaF PET/CT. The use of MRI will not 
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be feasible for all patients, as, due to its small diameter (60 cm), not all FOP patients will be 
able to fit in a regular machine. Ultrasound is quicker and patient friendlier(10,11), but will not 
be able to replace MRI in the evaluation of these oedematous lesions, as they are 
asymptomatic. 
FOP patients might encounter conditions that need surgical intervention(12,13). The patient. 
described in this thesis, was known with quiescent disease for a long period. Chronic 
infection and especially continuous antibiotic treatment may have led to the this silent state 
of disease. This is supported by the finding that months after surgical removal of the source 
of infection and discontinuation of the antibiotic treatment, increased 18F-NaF uptake was 
found in several HO lesions. The immune system has previously been thought to play an 
important role in FOP disease activity, as it has been described that immunosuppressant 
drugs also suppress flare-ups(14). The previous quiescence state, the careful management 
during surgery and the corticosteroid use may have led to the favourable outcome regarding 
the formed HO volume. The exact role of all factors described, need to be further investigated 
for its effect on HO formation. Despite a favourable outcome in this single patient, surgery 
is still highly contra-indicated in FOP patients(15,16). Surgery should only be considered as a 
last resort. In addition, anaesthetic procedures are challenging due to the jaw ankylosis, the 
inability to extent the neck and the severely affected pulmonary function and should 
therefore only be performed in a FOP expertise center(17,18). Hopefully, when a therapeutic 
drug to prevent HO formation is available, surgical procedures can be performed to unlock 
joints(19). 18F-NaF PET/CT should be the first choice for assessing the effects of these 
procedures on local and overall disease activity. 
As surgery is contraindicated, radiotherapy is preferred for the treatment of malignancies 
in FOP patients, even though effects of radiotherapy on disease activity have never been 
evaluated properly. High dose (54 Gray) radiotherapy for skin cancer was found safe with 
respect to FOP disease activity, but its long-term effects on FOP disease are unknown. 
Furthermore, the effect of high-dose radiotherapy for treatment of less superficial tumours, 
e.g. breast, liver or colon tumours, on FOP disease activity is not known. In the past, 
radiotherapy has also been used in an attempt to prevent HO formation, and some authors 
even claim that low doses (<10 Gray) are beneficial(20,21). The latter claim should, however, 
be interpreted with care, as it was primarily based only on subjective relieve of symptoms. 
When radiotherapy is considered, treatment could be monitored using 18F-NaF PET/CT to 
evaluate its effect on disease activity. 
HR-pQCT could be used to monitor the effects of a drug on HO, when it is expected to also 
affect existing HO. In addition, effects of the study drug on normal skeletal bone can be 
evaluated. Furthermore, HR-pQCT scans could gain more insight in the development of HO 
when obtained sequentially and during and after a flare-up. Its radiation exposure is ≈ 3 




measurements of bone density and trabecular microarchitecture are comparable with that 
of established imaging techniques, with coefficients of variation of 1.5% to 4.4% (23). For 
follow-up measurements, the primary concern is to rescan exactly the same region. It should 
be noted though, that reproducibility is only known for standard tibia and radius scans. In 
addition, reference values for HR-pQCT only include these two regions, making generalization 
for all other sites difficult. The downside of this technique is that only the distal radius and 
tibia can be scanned, whereas HO often forms more peripherally(1). Also, it requires almost 
normal mobility of the arms and legs. Therefore, this technique will only be feasible in a 
small subset of FOP patients. 
The presence of restrictive pulmonary function in early childhood might indicate that early 
in the course of the disease essential muscles or tendons for breathing are affected. It is 
not a congenital feature of FOP, as not all FOP patients have restrictive pulmonary function. 
Patients included in the present thesis were all diagnosed with FOP around the age of 5 to 
8 years. Whether FOP patients, who experience their first flare-up in adolescence, develop 
an equally severe restrictive pulmonary function, is not known. 
In the absence of a treatment, it is important to maintain pulmonary function through non-
medical treatments, such as breathing exercises and singing. The effectiveness of these 
exercises have not been confirmed in FOP patients, but are valuable in patients with 
restrictive lung disease(24). The effect of these exercises on maintaining pulmonary function 
in FOP patients should be further investigated. 
Clinical implications
The main conclusion of the work described in this thesis is that more insight in the 
development, progression and persistence of HO can be obtained using imaging techniques. 
In addition, based on these findings, a scheme can be proposed that defines specific imaging 
technique for the various phases of the disease (Figure 1). If there is (suspicion of) a flare-up, 
either an MRI or an 18F-NaF PET/CT could be prescribed. An MRI could be especially valuable 
in children, as there it does not expose a patient to radiation. If there is suspicion of a flare-
up, but no oedematous lesion is seen on MRI, an alternative diagnosis should be considered. 
The presence of oedema cannot distinguish an ossifying from a non-ossifying flare-up. In 
addition, it should be noted that oedema is non-specific, and therefore also other causes 
for oedema should be considered. The 18F-NaF PET/CT scan can predict the fate of a flare-
up. This finding can alter therapeutic decisions. Apart from this, 18F-NaF PET/CT can also be 
helpful to support the patient during a flare-up. Patients often fear loss of mobility during 
a flare-up, and especially its unpredictable character might be difficult to cope with. 
Finally, using 18F-NaF PET/CT, a chronic disease component was discovered. This provides 
a means to gain insight in disease activity of individual patients. Progressive immobilization 





















































































































































































































































































































The coming few years is an exciting time for everyone involved in the field of FOP: all eyes 
are on the clinical trials that are currently conducted. These trials will not only give 
information about the efficacy of the study drug, it will also expand our knowledge about 
the pathophysiology of FOP. In this thesis, small numbers of patients are reported, due to 
the rarity of the disease. Those clinical trials however, are conducted throughout various 
continents including a relatively large number of FOP patients. The knowledge gained from 
this thesis could be used and confirmed in these trials. For instance, Regeneron 
Pharmaceuticals Inc. is conducting a clinical trial in which Activin A antibodies are tested for 
their efficacy to halt HO formation. The 18F-NaF PET/CT, valuable as an imaging tool as shown 
in this thesis, is the primary endpoint of the study. The placebo group in this trial could be 
used to confirm our finding that flare-ups are accompanied with 18F-NaF uptake and that 
HO progresses chronically. Furthermore, the pulmonary function of patients on study drug 
can be compared to the longitudinal data shown in this thesis. Although MRI, does not have 
a place yet in those clinical trials, further research should explore the meaning of the mild 
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Fibrodysplasia ossificans progressiva (FOP) is een zeer zeldzaam, aangeboren ziektebeeld, 
waarbij er bot wordt gevormd in spieren en pezen. Het extra bot dat wordt gevormd, wordt 
heterotopisch bot genoemd. De vorming van dit heterotopisch bot kan worden veroorzaakt 
door beschadiging van een spier of pees. Dit gebeurt bijvoorbeeld tijdens een operatie, 
maar ook minder ingrijpende oorzaken zoals een vaccinatie of een val, kunnen tot de 
vorming van heterotopisch bot leiden. Soms ontstaat het echter spontaan: er is dan geen 
aanleiding aanwijsbaar. Voordat er heterotopisch bot wordt gevormd, ontstaat er zwelling, 
roodheid en pijn op de plek van de uiteindelijke botvorming. Deze lichamelijke verschijnselen 
noemen we een ‘flare-up’. De leeftijd waarop een patiënt de eerste flare-up krijgt, loopt erg 
uiteen, maar is gemiddeld rond het 6e levensjaar. Het heterotopische bot vormt zich op 
deze leeftijd vaak in de spieren van de borstkas, rug en nek. Met toename van de leeftijd, 
vormen de flare-ups zich steeds meer in de ledematen, waardoor schouders, heupen, knieën 
en ellebogen op slot komen te zitten. Als gevolg hiervan is de patiënt vaak rond het dertigste 
levensjaar afhankelijk van een rolstoel en heeft de patiënt hulp nodig van anderen voor de 
dagelijkse activiteiten. De leeftijdsverwachting van een patiënt met FOP is beperkt door het 
heterotopische bot dat zich rondom de borstkas heeft gevormd. De longen kunnen zich 
hierdoor onvoldoende uitzetten tijdens de ademhaling, waardoor de functie van de longen 
slechter is en een longontsteking al kan leiden tot het overlijden van de patiënt. Het 
natuurlijke beloop van deze longfunctiestoornis door de jaren heen is niet bekend, ook is 
niet bekend of een patiënt met veel heterotopische bot rondom de borstkas in de regel ook 
een slechtere longfunctie heeft. 
Heterotopisch bot
In 2006 is het genetisch defect bij patiënten met FOP ontdekt. Dit heeft ervoor gezorgd dat 
we meer te weten zijn gekomen over deze aandoening. Echter, er is nog steeds veel 
onbekend over het heterotopische bot dat zich vormt in patiënten met FOP. Zo blijkt uit 
een enquête onder vijfhonderd FOP patiënten, dat twintig procent van de flare-ups weg 
gaat zonder dat er uiteindelijk heterotopisch bot wordt gevormd. Waarom de ene flare-up 
wel tot botvorming leidt, en de ander niet is onbekend. Verder bleek uit deze enquête dat 
vijftig procent van de patiënten het gevoel had dat het heterotopisch bot toenam in grootte 
zonder dat er symptomen van een flare-up aanwezig waren. Doordat er tot op heden geen 
bloedtest is die activiteit van de ziekte kan aantonen, is het niet mogelijk geweest om 
bovenstaande processen objectief aan te tonen. Ook kan men daardoor de effecten van 
invasieve behandelingen (bijv. chirurgie en radiotherapie) op de activiteit van FOP niet goed 
beoordelen. Alternatieven om ziekte activiteit aan te tonen moeten dus gezocht worden, 
om de botvorming die plaatsvindt bij deze ziekte inzichtelijker te maken. Omdat technieken 




zullen niet-invasieve technieken gebruikt moeten worden om meer inzicht in het extra bot 
te krijgen. Beeldvormende technieken zouden de kennis over het bot, het ontstaan en de 
ontwikkeling van het bot in kaart kunnen brengen, zonder dat het de ziekte verergert. Een 
mogelijke beeldvormende techniek die gebruikt kan worden, is de PET-scan. De PET-scan 
is voornamelijk bekend voor onderzoek naar uitzaaiingen bij kanker. Hierbij wordt gebruik 
gemaakt van radioactief glucose (suiker) dat aan de tumor en de uitzaaiingen bindt. De 
PET-scan kan echter ook gebruikt worden om actieve botvorming op te sporen, door een 
radioactieve stof, 18F-NaF, toe te dienen die specifiek bindt aan botcellen. De PET-scan wordt 
altijd in combinatie met een CT-scan gemaakt. Met CT-scan kan gevormd bot worden 
afgebeeld en gemeten. De waarde van de 18F-NaF PET/CT bij het aantonen van ziekte 
activiteit, c.q. botvorming, bij FOP, is nog niet bekend. 
Voor kinderen zal de toepassing van een PET-scan niet altijd wenselijk zijn, aangezien bij de 
PET-scan relatief veel straling wordt gebruikt. Bij kinderen, die nog in de groei zijn, kan 
straling een verhoogde kans op kanker geven. De MRI-scan, een beeldvormende techniek 
zonder deze stralingsbelasting, kan een alternatief zijn. De waarde van deze techniek bij 
patiënten met FOP is echter nog niet onderzocht. 
Als na een flare-up, heterotopisch bot zich uiteindelijk heeft gevormd, wordt gedacht dat 
het heterotopische bot hetzelfde is als het bot van het skelet. Echter, dit is nauwelijks 
onderzocht, aangezien een botbiopt, een techniek waarbij een stukje bot wordt verwijderd 
voor analyse, niet mogelijk is bij FOP patiënten. Een botbiopt zorgt namelijk voor een 
beschadiging, wat weer een flare-up veroorzaakt. Recent is er een nieuwe beeldvormende 
techniek ontwikkeld, de HR-pQCT-scan, welke het mogelijk maakt om het bot in de 
onderarmen en -benen te analyseren zonder dat er daarbij schade wordt toegebracht aan 
de patiënt. Heterotopisch bot dat zich in de onderarmen en -benen bevindt, zou op deze 
manier onderzocht kunnen worden zonder de patiënt te schaden. 
Doel proefschrift
Dit proefschrift heeft als doel om de ontwikkeling en het natuurlijke beloop van heterotopisch 
bot te onderzoeken, evenals de structuur van het heterotopisch bot zelf en het effect van 
heterotopisch bot op de longfunctie van FOP patiënten.
In het proefschrift is onderzocht of ziekte activiteit tijdens een flare-up aantoonbaar is 
middels de 18F-NaF PET-scan en de MRI-scan. Ook is het natuurlijke beloop van heterotopisch 
bot onderzocht middels de 18F-NaF PET/CT-scan. Verder is het effect van een operatie en 
bestraling op de FOP ziekte activiteit onderzocht. 
De structuur van volgroeid heterotopische bot is onderzocht middels een HR-pQCT-scan. 




In hoofdstuk 2 zijn meerdere spontane flare-ups bij één patiënt vervolgd met de 18F-NaF 
PET/CT-scan. Zelfs voordat er op de CT-scan aanwijzingen waren voor botvormingen, was 
er al activiteit te zien op de 18F-NaF PET-scan. Het bot dat uiteindelijk was gevormd, had zich 
alleen gevormd in de gebieden waar de PET-scan de activiteit toonde. In hoofdstuk 3 werd 
het natuurlijke beloop van heterotopisch bot gevolgd over een tijdspanne van 6-18 maanden 
middels de 18F-NaF PET/CT-scan. Er werd gevonden dat, zelfs in de afwezigheid van klachten, 
heterotopisch bot in grootte kan toenemen. De hoeveelheid bot die wordt gevormd tijdens 
deze ‘chronisch fase’ is veel minder vergeleken met bot dat ontstaat als gevolg van een 
flare-up. In hoofdstuk 4 werden vier patiënten beschreven die zowel MRI-scans als 18F-NaF 
PET/CT-scans hadden ondergaan. Door de PET-scan als gouden standaard te gebruiken, 
werd aangetoond dat de flare-ups met de MRI-scan aantoonbaar zijn, doordat er een 
vochtophoping (oedeem) te zien is ter plaatse van de flare-up. Echter, de aanwezigheid van 
dit vocht heeft geen voorspellende waarde wat betreft het gevolg (botvormend of niet-
botvormend) van de flare-up. Wel werden er in FOP patiënten milde vochtophopingen gezien 
op plaatsen in het lichaam waar de patiënten geen klachten ervaarde. De betekenis van 
dergelijke vochtophopingen bij FOP, gezien deze bij gezonde personen niet aanwezig zijn, 
moet verder worden onderzocht. In hoofdstuk 5 is het effect van een levensreddende 
operatie op de ziekteactiviteit – zowel flare-ups als chronische toename – beschreven. De 
beschreven patiënt leed al jaren aan een chronische infectie van haar voet, waarvoor zij een 
onderbeenamputatie moest ondergaan. Zij had vooraf aan de operatie al jaren geen ziekte 
activiteit meer gehad, zoals gemeten middels 18F-NaF PET-scan. Zowel de anesthesie als de 
chirurgie waren succesvol, nadien vormde er slechts een minimale hoeveelheid heterotopisch 
bot ter plaatse van de operatie. Wel werd 12 maanden na de operatie, voor het eerst sinds 
jaren, weer ziekte activiteit in het lichaam waargenomen op de 18F-NaF PET-scan. In hoofdstuk 
6 wordt een patiënt beschreven die radiotherapie (bestraling) onderging voor huidkanker 
van de lip. Een hoge dosis bestraling zoals gebruikt bij deze FOP patiënt was in de literatuur 
niet eerder beschreven. Lagere dosis radiotherapie lieten wel al zien veilig te zijn, alhoewel 
deze niet gevolgd waren middels de 18F-NaF PET-scan. De radiotherapeutische behandeling 
van deze patiënt zorgde niet voor een plaatselijke flare-up, en ook verhoogde ziekte activiteit 
elders in het lichaam werd niet waargenomen middels de PET-scan. 
In hoofdstuk 7 werden de HR-pQCT-scans van twee patiënten geanalyseerd. De architectuur 
van zowel skelet als heterotopisch bot werd onderzocht. Heterotopisch bot bleek qua 
structuur van de botbalkjes en de schors niet overeen te komen met het naburige normaal 
bot van het skelet, zoals eerder werd verondersteld. Ook de tibia – een bot in het onderbeen 
– bleek verschillend te zijn ten opzichte van gezonde leeftijdsgenoten. 
Tot slot, werden de effecten van het heterotopisch bot op de longen onderzocht in hoofdstuk 
8. Zeven FOP patiënten werden beschreven. Van hen waren longfunctie onderzoeken 
beschikbaar over een tijdspanne van 6-18 jaar. CT-beelden van vijf van hen werden 
geanalyseerd om de verband tussen longfunctie en het volume van het heterotopisch bot 




leek te verslechteren tot aan halverwege de 20. Bij de oudere patiënten, bleef de longfunctie 
stabiel over de gevolgde periode. De hoeveelheid heterotopisch bot leek geen verband te 
hebben met de ernst van de longfunctie. 
Discussie 
Met de 18F-NaF PET/CT-scan is het voor het eerst mogelijk om de ziekte activiteit in het 
lichaam van een FOP patiënt te meten. Er zijn nu verschillende medicijnen in ontwikkeling, 
waarmee men hoopt de heterotopische botvorming te stoppen. Deze medicijnen moeten 
niet alleen heterotopische botvorming na flare-ups voorkomen, maar ook verdere toename 
van al aanwezig heterotopisch bot voorkomen. Voor studies die de werkzaamheid van het 
middel op deze twee fasen in FOP patiënten onderzoeken, is een dergelijke marker voor 
ziekte activiteit essentieel. Het medicijn zou de bot activiteit moeten normaliseren. Naast 
het voorkomen van de vorming van heterotopisch bot, is het, voornamelijk bij de behandeling 
van kinderen met FOP, belangrijk dat de longfunctie behouden blijft. Gezien er op dit 
moment nog geen effectieve behandeling is voor FOP, is het belangrijk dat de longfunctie 
nu met niet-medicamenteuze therapie wordt behouden. Dit kan gepoogd worden middels 
ademhalingsoefeningen en zangoefeningen. Het effect hiervan op het behoud van de 
longfunctie in FOP is echter nog niet onderzocht.
De MRI-scan kan de 18F-NaF PET-scan nog niet vervangen: de aanwezigheid van 
vochtophopingen is niet specifiek voor FOP; dat wil zeggen dat er nog vele andere 
aandoeningen zijn waarbij er vochtophopingen kunnen ontstaan, De MRI-scan zegt daardoor 
onvoldoende over de FOP ziekte activiteit die uiteindelijk tot heterotopische botvorming 
leidt. Bij de 18F-NaF PET/CT-scan wordt een patiënt wel onderworpen aan straling en de 
beelden kunnen lastig te interpreteren zijn voor een arts of onderzoeker. Er blijft daarom 
een vraag naar een (eenvoudige) bloedtest om de ziekte activiteit aan te tonen. In de 
zoektocht naar deze bloedtest, kan men de uitkomsten van het bloed vergelijken met de 
activiteit op de 18F-NaF PET-scan. Indien beide overeenkomen, weet men dat het een 
betrouwbare bloedtest in handen heeft. 
Door 18F-NaF PET/CT-scans te maken voor en na invasieve behandelingen bij FOP-patiënten 
komen we meer te weten over de effecten die deze behandelingen hebben op deze 
bijzondere aandoening. Bijzonder is het minimale heterotopische bot dat zich vormde na 
een onderbeen amputatie. Ondanks deze positieve uitkomst, dient een operatie te allen 
tijde voorkomen te worden bij FOP patiënten. Het immuunsysteem speelt een belangrijke 
rol bij FOP, en mogelijk dat ofwel de chronische infectie ofwel het continue gebruik van 
antibiotica bij deze patiënte heeft geleid tot een onderdrukking van de FOP ziekte. Verder 
onderzoek zal moeten uitwijzen of FOP patiënten met chronische infectieuze aandoeningen 
inderdaad een lagere ziekte activiteit op de 18F-NaF PET/CT-scan laten zien, vergeleken met 
andere FOP patiënten. 
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De toepassing van de HR-pQCT-scan in de klinische zorg voor FOP patiënten is discutabel. 
Doordat alleen de onderarmen en –benen gescand kunnen worden, en er flexibiliteit van 
de heupen en knieën nodig is voor een goede positie in de scanner, zullen veel patiënten 
niet in aanmerking komen om gescand te worden. Voor onderzoek echter, kan deze nieuwe 
beeldvormende techniek ons inzicht geven in een in de ontwikkeling van heterotopisch bot, 
wanneer tijdens een flare-up systematisch HR-pQCT-scans zouden worden gemaakt. 
Uiteraard zal dan eerst een 18F-NaF PET/CT-scan gemaakt moeten worden om aan te tonen 




Contributing Authors and Affiliations 
J. van den Aardweg, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, de Boelelaan 
1117, Amsterdam, The Netherlands
J.P. van den Bergh, MD PhD
Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands
M.S.A.M. Bevers 
Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands
A. Bökenkamp, MD PhD
Amsterdam UMC, Emma Children’s Hospital, Vrije Universiteit Amsterdam, Department of 
Pediatric Nephrology, de Boelelaan 1117, Amsterdam, The Netherlands
A. Boonstra. MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, de Boelelaan 
1117, Amsterdam, The Netherlands
N. Bravenboer, PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Chemistry, 
Amsterdam Bone Center, Amsterdam Movement Sciences, De Boelelaan 1117, Amsterdam, 
the Netherlands
M. Dahele, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiation Oncology, de 
Boelelaan 1117 The Netherlands
E.M.W. Eekhoff, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine section 
Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, de Boelelaan 
1117, Amsterdam, the Netherlands
D. González Trotter, PhD
Regeneron Pharmaceuticals, Inc., New York, United States of America
P. de Graaf, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 
Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
Addendum
146
Z. Grunwald, MD PhD
Thomas Jefferson University, Jefferson Health system, Department of Anesthesiology, 
Philadelphia, Pennsylvania 19107, USA
M. Hoebink, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine section 
Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, de Boelelaan 
1117, Amsterdam, the Netherlands
P.M.C. Jak
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, de Boelelaan 
1117, Amsterdam, The Netherlands
O. Kamp, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Cardiology, de Boelelaan 
1117, Amsterdam, The Netherlands
P. Koolwijk, PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Physiology, the Netherlands
A.A. Lammertsma, PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 
Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
W.D. Lubbers, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anesthesiology, De Boelelaan 
1117, Amsterdam, the Netherlands
D. Micha, PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, Amsterdam 
Bone Center, Amsterdam Movement Sciences, De Boelelaan 1117, Amsterdam, the 
Netherlands
J.C. Netelenbos, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine section 
Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, de Boelelaan 
1117, Amsterdam, the Netherlands
J.A. Nieuwenhuijzen, MD PhD






Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, Amsterdam 
Bone Center, Amsterdam Movement Sciences, the Netherlands
E.J.G. Peters, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine Section 
of Infectious Diseases, Amsterdam Movement Sciences, De Boelelaan 1117, Amsterdam, 
the Netherlands
P.G.H.M. Raijmakers, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 
Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
B. van Rietbergen, PhD
Orthopedic Biomechanics, Department of Biomedical Engineering, Eindhoven University of 
Technology, Eindhoven, The Netherlands
T. Rustemeyer, MD PhD
Amsterdam UMC, University of Amsterdam, Department of Dermatology, Meibergdreef 9, 
Amsterdam, Netherlands
L. Sabelis, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Rehabilitation Medicine, De 
Boelelaan 1117, Amsterdam, the Netherlands
A. van Schie, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 
Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
P.R. Schober, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anesthesiology, De Boelelaan 
1117, Amsterdam, the Netherlands
T. Schoenmaker
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University 
of Amsterdam and Vrije Universiteit
L.J. Schoonmade 




L.A. Schwarte, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anesthesiology, De Boelelaan 
1117, Amsterdam, the Netherlands
B.J. Smilde, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine section 
Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, de Boelelaan 
1117, Amsterdam, the Netherlands
J.M. Smit, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Plastic, Reconstructive and 
Hand Surgery, Amsterdam Bone Center, De Boelelaan 1117, Amsterdam, the Netherlands
B.P. Teunissen, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 
Medicine, De Boelelaan 1117, Amsterdam, the Netherlands
S. Treurniet, MD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine section 
Endocrinology, Amsterdam Bone Center, Amsterdam Movement Sciences, de Boelelaan 
1117, Amsterdam, the Netherlands
M.C. Visser, MD PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Neurology, De Boelelaan 
1117, Amsterdam, the Netherlands
T.J. de Vries, PhD
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University 
of Amsterdam and Vrije Universiteit
R. de Vries
Medical Library, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, the 
Netherlands
C.E. Wyers, PhD
Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands
M. Yaqub, PhD
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear 





ACVR1 = Activin A receptor type 1
ALK2 = Activin receptor-like kinase-2
Ar = area
BCC = basal cell carcinoma
BMP = bone morphogenetic protein
Bq = becquerel
CAJIS = cumulative analogue joint involvement scale
CT = computed tomography
Ct.Po = cortical porosity
Ct.Th = cortical thickness 
Ct = cortical
DCLO = diffusing capacity for carbon dioxide
DCLO/VA = diffusing capacity for carbon dioxide corrected for alveolar volume
FDG = fluordeoxyglucose
FEV1 = forced expiratory volume in one second
FKBP12 = FK506 binding protein 12
18F-NaF = fluorine-18 labelled sodium fluoride 
FOP = fibrodysplasia ossificans progressiva
FVC = forced vital capacity
GS-domain: glycine-serine (GS) domain
Gy = gray
HO = heterotopic ossification
HR-pQCT = high-resolution peripheral quantitative computed tomography
HU = hounsfield units
MAPK= mitogen-activated protein kinase
MBq = mega becquerel 
MDP = methylene diphosphonate
MOT = myositis ossificans traumatica
MRI = magnetic resonance imaging
msv = milisievert 
NSAID = nonsteroidal anti-inflammatory drug
PET = positron emission tomography
PFT = pulmonary function test
ROI = region of interest 
RT= radiotherapy
RV = residual volume





Tb.BV/TV = trabecular bone volume fraction
Tb.N = trabecular number
Tb.1/N.SD = heterogeneity of the trabecular network
Tb.Sp = trabecular separation
Tb.Th = trabecular thickness
99mTc = technetium-99m 
Tt = total
TLC = total lung capacity
TMJ = temporomandibular joint
vBMD = volumetric bone mineral density
VC = vital capacity
VOI = volume of interest
WBLDCT = whole body low dose computed tomography 
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